

Safety and Immunogenicity of Two RNA-Based Covid-1

New England Journal of Medicine

383, 2439-2450

DOI: [10.1056/nejmoa2027906](https://doi.org/10.1056/nejmoa2027906)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
2	RNA Vaccines for COVID-19. <i>JACC Basic To Translational Science</i> , 2020, 5, 1240-1243.	1.9	7
3	SARS coronavirus 2: from genome to infectome. <i>Respiratory Research</i> , 2020, 21, 318.	1.4	62
4	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2020, 383, 2603-2615.	13.9	11,472
5	Coronavirus vaccine development: from SARS and MERS to COVID-19. <i>Journal of Biomedical Science</i> , 2020, 27, 104.	2.6	287
6	COVID-19: Coronavirus Vaccine Development Updates. <i>Frontiers in Immunology</i> , 2020, 11, 602256.	2.2	143
7	Flu RNA Vaccine: A Game Changer?. <i>Vaccines</i> , 2020, 8, 760.	2.1	2
8	Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials. <i>Vaccines</i> , 2020, 8, 746.	2.1	6
9	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
10	Nucleic Acid-Based Technologies Targeting Coronaviruses. <i>Trends in Biochemical Sciences</i> , 2021, 46, 351-365.	3.7	35
11	Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 1635-1649.	1.4	14
12	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. <i>Advanced Drug Delivery Reviews</i> , 2021, 169, 168-189.	6.6	62
13	Individual and community-level risk for COVID-19 mortality in the United States. <i>Nature Medicine</i> , 2021, 27, 264-269.	15.2	70
14	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
15	Viral targets for vaccines against COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 73-82.	10.6	832
16	Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000041.	1.7	37
17	The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world. <i>Lancet, The</i> , 2021, 397, 68-70.	6.3	33
19	COVID-19 vaccines. <i>Farmacist Ro</i> , 2021, 1, 7.	0.0	0

#	ARTICLE	IF	CITATIONS
20	Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	0.7	9
21	Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines. <i>Immune Network</i> , 2021, 21, e29.	1.6	14
22	Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials. <i>Global Health Action</i> , 2021, 14, 1892309.	0.7	14
24	Engineering SARS-CoV-2 using a reverse genetic system. <i>Nature Protocols</i> , 2021, 16, 1761-1784.	5.5	137
25	Cancer Vaccines: Antigen Selection Strategy. <i>Vaccines</i> , 2021, 9, 85.	2.1	30
26	T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	20
27	An Update on Self-Amplifying mRNA Vaccine Development. <i>Vaccines</i> , 2021, 9, 97.	2.1	117
29	Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. <i>Emerging Microbes and Infections</i> , 2021, 10, 629-637.	3.0	118
30	Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. <i>Emerging Microbes and Infections</i> , 2021, 10, 1598-1608.	3.0	76
31	COVID-19 vaccines: where we stand and challenges ahead. <i>Cell Death and Differentiation</i> , 2021, 28, 626-639.	5.0	626
32	COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology. <i>Journal of Korean Medical Science</i> , 2021, 36, e95.	1.1	40
33	RNA-Based COVID-19 Vaccine Candidates with Clinical Phase Trials in Progress. <i>Turkish Journal of Medical Sciences</i> , 2021, , , .	0.4	0
34	Vaccinations in CLL: implications for COVID-19. <i>Blood</i> , 2021, 137, 144-146.	0.6	20
36	A phytochemical-based medication search for the SARS-CoV-2 infection by molecular docking models towards spike glycoproteins and main proteases. <i>RSC Advances</i> , 2021, 11, 12003-12014.	1.7	17
37	Vitamin D Modulation of the Innate Immune Response to Paediatric Respiratory Pathogens Associated with Acute Lower Respiratory Infections. <i>Nutrients</i> , 2021, 13, 276.	1.7	18
38	Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers; Changing Epidemiology as the Pandemic Progresses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
39	COVID-19: Characteristics and Therapeutics. <i>Cells</i> , 2021, 10, 206.	1.8	177
40	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. <i>Open Life Sciences</i> , 2021, 16, 558-570.	0.6	8

#	ARTICLE	IF	CITATIONS
42	What is the status of nucleic acid contamination in 2019-nCoV vaccination sites? Can it be avoided?. <i>Epidemiology and Infection</i> , 2021, 149, 1-23.	1.0	1
43	The Impact of COVID-19 Pandemic on Lung Cancer Community. <i>World Journal of Oncology</i> , 2021, 12, 1-6.	0.6	8
44	Immunological Changes in Pregnancy and Its Relation to COVID-19 Infection. , 2021, , 23-37.		0
45	Why two doses of the BNT162b2 mRNA Covid-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA Covid-19 and other vaccines. <i>Panminerva Medica</i> , 2021, , .	0.2	4
46	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. <i>ACS Central Science</i> , 2021, 7, 183-199.	5.3	134
47	Development of mRNA Vaccines: Scientific and Regulatory Issues. <i>Vaccines</i> , 2021, 9, 81.	2.1	56
49	Acute treatment with monoclonal antibodies: their design and their use. <i>Microbiology Australia</i> , 2021, 42, 39.	0.1	0
51	Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development. <i>Cancer Biology and Medicine</i> , 2021, 18, 352-371.	1.4	22
53	TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases. <i>Pharmaceutics</i> , 2021, 13, 142.	2.0	129
54	Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in South Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e153.	1.1	45
55	Antibodies, epicenter of SARS-CoV-2 immunology. <i>Cell Death and Differentiation</i> , 2021, 28, 821-824.	5.0	9
56	The Worldwide Effort to Develop Vaccines for COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 215-223.	0.8	3
58	Membrane Microvesicles as Potential Vaccine Candidates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1142.	1.8	11
60	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000063.	1.7	5
61	Review of Covid-19 vaccine clinical trials - A puzzle with missing pieces. <i>International Journal of Biological Sciences</i> , 2021, 17, 1461-1468.	2.6	37
62	BNT162b2 Vaccine-Induced Immune Responses and Dynamics Vary Among Age Groups, Sex and Co-Morbidities: A Longitudinal Prospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
63	A <i>Trans</i>-Complementation System for SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
64	Vaccine responses in ageing and chronic viral infection. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	3

#	ARTICLE	IF	CITATIONS
65	Doctorâ€™Should I get the <scp>COVID</scp>â€19 vaccine? Infection and immunization in individuals with neuromuscular disorders. <i>Muscle and Nerve</i> , 2021, 63, 294-303.	1.0	29
67	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	0.4	3
68	Antibody Titers 3-Months Post-Vaccination with the Pfizer/Biontech Vaccine in Greece. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
69	lluminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. <i>Biomaterials Science</i> , 2021, 9, 4289-4300.	2.6	52
70	mRNA vaccines for COVID-19: what, why and how. <i>International Journal of Biological Sciences</i> , 2021, 17, 1446-1460.	2.6	185
71	SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 36.	2.1	41
72	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. <i>Genome Medicine</i> , 2021, 13, 7.	3.6	193
73	SARS-CoV-2: vaccines in the pandemic era. <i>Military Medical Research</i> , 2021, 8, 1.	1.9	104
75	Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. <i>Vaccines</i> , 2021, 9, 61.	2.1	105
77	WHF Position Statement on COVID Vaccination. <i>Global Heart</i> , 2021, 16, 29.	0.9	1
78	Evolution of Antibody Titers Up to 6 Months Post-Immunization With the BNT162b2 Pfizer/BioNTech Vaccine in Greece. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
79	COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: CommuniquÃ© From the Canadian Association of Gastroenterology. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 49-49.	0.1	13
80	Specific measures to response pandemic of COVID-19 in China: a systematic review. <i>E3S Web of Conferences</i> , 2021, 292, 03076.	0.2	0
81	Nanomedicine for vaccination and diagnosis of diseases. <i>Nanomedicine</i> , 2021, 16, 165-169.	1.7	0
83	COVID-19 basics and vaccine development with a Canadian perspective. <i>Canadian Journal of Microbiology</i> , 2021, 67, 112-118.	0.8	3
85	Promoting versatile vaccine development for emerging pandemics. <i>Npj Vaccines</i> , 2021, 6, 26.	2.9	26
87	Making sense of spike D614G in SARS-CoV-2 transmission. <i>Science China Life Sciences</i> , 2021, 64, 1062-1067.	2.3	8
88	Immune thrombocytopenia in a <scp>22</scp>â€yearâ€old post <scp>C</scp>ovidâ€<scp>19</scp> vaccine. <i>American Journal of Hematology</i> , 2021, 96, E133-E134.	2.0	99

#	ARTICLE	IF	CITATIONS
89	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. <i>RMD Open</i> , 2021, 7, e001594.	1.8	59
90	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
95	How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?. <i>Diabetes</i> , 2021, 70, 1021-1028.	0.3	2
96	Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19. <i>Heliyon</i> , 2021, 7, e06350.	1.4	86
98	COVID-19(â€žcoronavirus disease 2019â€œ)-Impfung. <i>DGNeurologie</i> , 2021, 4, 75-77.	0.0	0
100	SARSâ€œCoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. <i>Infectious Disease Reports</i> , 2021, 13, 102-125.	1.5	24
101	New drug: BNT162b2 vaccine for prevention of COVID-19. <i>Australian Prescriber</i> , 2021, 44, 57-58.	0.5	3
102	HIV mRNA Vaccinesâ€œProgress and Future Paths. <i>Vaccines</i> , 2021, 9, 134.	2.1	45
103	Unanticipated efficacy of SARS-CoV-2 vaccination in older adults. <i>Immunity and Ageing</i> , 2021, 18, 7.	1.8	20
105	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 397, 682-694.	6.3	235
106	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. <i>Journal of Hematology and Oncology</i> , 2021, 14, 38.	6.9	87
108	Approved mRNA Vaccines for SARS-CoV-2. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 17-18.	0.2	2
110	A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. <i>Protein Journal</i> , 2021, 40, 260-295.	0.7	24
111	Synthetic biology in the clinic: engineering vaccines, diagnostics, and therapeutics. <i>Cell</i> , 2021, 184, 881-898.	13.5	56
112	COVID-19 mRNA vaccines. <i>Journal of Genetics and Genomics</i> , 2021, 48, 107-114.	1.7	59
113	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. <i>Vaccines</i> , 2021, 9, 147.	2.1	175
114	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
116	Polymerâ€œLipid Pharmaceutical Nanocarriers: Innovations by New Formulations and Production Technologies. <i>Pharmaceutics</i> , 2021, 13, 198.	2.0	35

#	ARTICLE	IF	CITATIONS
117	Identification of HLA-A*02:01-Restricted Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 That May Be Natural Targets of CD8 ⁺ T Cell Recognition <i>In Vivo</i> . <i>Journal of Virology</i> , 2021, 95, .	1.5	20
118	COVID-19 Vaccination for Persons with Parkinson's Disease: Light at the End of the Tunnel?. <i>Journal of Parkinson's Disease</i> , 2021, 11, 3-8.	1.5	21
119	Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. <i>Transplantation</i> , 2021, 105, e56-e57.	0.5	62
121	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. <i>Nature</i> , 2021, 592, 283-289.	13.7	494
122	COVID-19 Vaccine Acceptance in the Democratic Republic of Congo: A Cross-Sectional Survey. <i>Vaccines</i> , 2021, 9, 153.	2.1	102
123	Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines. <i>RMD Open</i> , 2021, 7, e001553.	1.8	23
125	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. <i>Vaccines</i> , 2021, 9, 171.	2.1	43
127	Key facts about the COVID-19 vaccination programme in the UK. <i>Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals</i> , 2021, 13, 56-58.	0.0	1
128	Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection. <i>Journal of Ovarian Research</i> , 2021, 14, 39.	1.3	5
130	Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 48.	7.1	79
132	COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment. <i>Archives of Dermatological Research</i> , 2022, 314, 1-15.	1.1	99
133	Development and deployment of COVID-19 vaccines for those most vulnerable. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	60
134	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 615240.	2.2	59
135	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. <i>Npj Vaccines</i> , 2021, 6, 28.	2.9	507
136	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. <i>Nature Medicine</i> , 2021, 27, 620-621.	15.2	562
137	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
139	Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. <i>Vaccines</i> , 2021, 9, 316.	2.1	11
140	Eighty-Seven Consecutive Sleeve Gastrectomies Between the Two Peaks of the Covid-19 Pandemic. An Opening-Phase Experience. <i>Obesity Surgery</i> , 2021, 31, 3026-3030.	1.1	5

#	ARTICLE	IF	CITATIONS
142	Artificial Bioaugmentation of Biomacromolecules and Living Organisms for Biomedical Applications. <i>ACS Nano</i> , 2021, 15, 3900-3926.	7.3	28
143	Genomic and healthcare dynamics of nosocomial SARS-CoV-2 transmission. <i>ELife</i> , 2021, 10, .	2.8	35
145	Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 104, 441-451.	1.5	14
146	State-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 14816-14843.	4.0	27
147	Does COVID-19 Vaccination Warrant the Classical Principle "eifelein i mi vlapinâ€?. <i>Medicina (Lithuania)</i> , 2021, 57, 253.	0.8	10
148	Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic. <i>Journal of Infectious Diseases</i> , 2022, 226, 1357-1361.	1.9	30
149	The conundrum of current anti-SARS-CoV-2 vaccines. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 46-51.	3.2	6
152	The potential neurological effect of the COVIDâ€19 vaccines: A review. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 3-12.	1.0	85
153	Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration. <i>Transplantation</i> , 2021, 105, e72-e73.	0.5	64
155	SARS-CoV-2 vaccines in patients with SLE. <i>Lupus Science and Medicine</i> , 2021, 8, e000479.	1.1	30
156	Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. <i>Lancet, The</i> , 2021, 397, 1057-1058.	6.3	360
157	mRNA SARS-CoV-2 Immunization Confers Robust Antibody Response in Occupational Healthcare Workers and Fosters Workplace Safety. <i>Journal of Occupational and Environmental Medicine</i> , 2021, 63, e314-e317.	0.9	3
158	Mass vaccination campaign for residents and workers and assistance to vulnerable populations during COVID-19 pandemic: The experience of the healthcare services of the Vatican City. <i>Lancet Regional Health - Europe, The</i> , 2021, 2, 100053.	3.0	2
159	Self-assembled mRNA vaccines. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 83-112.	6.6	248
160	Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?. <i>Lancet, The</i> , 2021, 397, 879-880.	6.3	29
163	Development of COVID-19 vaccines utilizing gene therapy technology. <i>International Immunology</i> , 2021, 33, 521-527.	1.8	19
164	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. <i>Science Advances</i> , 2021, 7, .	4.7	80
165	Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. <i>Clinical Drug Investigation</i> , 2021, 41, 499-509.	1.1	14

#	ARTICLE	IF	CITATIONS
166	Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. <i>Frontiers in Immunology</i> , 2021, 12, 657711.	2.2	50
167	Assessing Antigen Structural Integrity through Glycosylation Analysis of the SARS-CoV-2 Viral Spike. <i>ACS Central Science</i> , 2021, 7, 586-593.	5.3	68
168	The Limitless Future of RNA Therapeutics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 628137.	2.0	296
169	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. <i>Npj Vaccines</i> , 2021, 6, 44.	2.9	36
172	Risk of SARS-CoV-2 reinfection after natural infection. <i>Lancet, The</i> , 2021, 397, 1161-1163.	6.3	53
173	COVID-19 vaccines: rapid development, implications, challenges and future prospects. <i>Human Cell</i> , 2021, 34, 711-733.	1.2	227
174	Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders. <i>Ophthalmology and Therapy</i> , 2021, 10, 201-209.	1.0	21
175	Cationic lipids for gene delivery: many players, one goal. <i>Chemistry and Physics of Lipids</i> , 2021, 235, 105032.	1.5	55
176	Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks â€” Connecticut, December 2020â€”February 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 396-401.	9.0	130
177	Distinct Characteristics of COVID-19 Infection in Children. <i>Frontiers in Pediatrics</i> , 2021, 9, 619738.	0.9	23
178	Adherence to COVID-19 Prevention Measures in the Democratic Republic of the Congo, Results of Two Consecutive Online Surveys. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2525.	1.2	14
179	High-throughput approaches of diagnosis and therapies for COVID-19: antibody panels, proteomics and metabolomics. <i>Future Drug Discovery</i> , 2021, 3, .	0.8	10
180	SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges. <i>Future Cardiology</i> , 2021, 17, 1277-1291.	0.5	9
181	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
182	Sterilizing Immunity against SARSâ€”CoVâ€”2 Infection in Mice by a Singleâ€”Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonistâ€”Adjuvanted Recombinant Spike Protein Vaccine**. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 9467-9473.	7.2	45
183	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. <i>Viruses</i> , 2021, 13, 418.	1.5	51
184	mRNA in cancer immunotherapy: beyond a source of antigen. <i>Molecular Cancer</i> , 2021, 20, 48.	7.9	46
185	Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. <i>Lancet, The</i> , 2021, 397, 1178-1181.	6.3	279

#	ARTICLE	IF	CITATIONS
186	COVID-19 in early 2021: current status and looking forward. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 114.	7.1	191
188	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	6.0	468
189	Charge-Conversion Strategies for Nucleic Acid Delivery. <i>Advanced Functional Materials</i> , 2021, 31, 2011103.	7.8	17
190	Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single Shot and Lipid Amphiphile Imdazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine**. <i>Angewandte Chemie</i> , 2021, 133, 9553-9559.	1.6	4
192	Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines. <i>Diagnostics</i> , 2021, 11, 579.	1.3	114
194	Considering Mandatory Vaccination of Children for COVID-19. <i>Pediatrics</i> , 2021, 147, .	1.0	38
197	Frontrunners in the race to develop a SARS-CoV-2 vaccine. <i>Canadian Journal of Microbiology</i> , 2021, 67, 189-212.	0.8	11
200	Clinical and immunological effects of mRNA vaccines in malignant diseases. <i>Molecular Cancer</i> , 2021, 20, 52.	7.9	90
201	Therapeutic RNA Delivery for COVID and Other Diseases. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002022.	3.9	31
202	Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1306-1311.	0.5	289
203	COVID-19 vaccine testing in pregnant females is necessary. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	39
204	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2021, 14, 331-346.	1.9	12
205	mRNA vaccines take on immune tolerance. <i>Nature Biotechnology</i> , 2021, 39, 419-421.	9.4	15
206	Development and implementation of a potential coronavirus disease 2019 (COVID-19) vaccine: A systematic review and meta-analysis of vaccine clinical trials. <i>Journal of College of Medical Sciences-Nepal</i> , 2021, 11, 959-982.	0.2	17
207	Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice. <i>Journal of the American Heart Association</i> , 2021, 10, e019506.	1.6	8
208	Determinants of COVID-19 vaccine acceptance in a high infection-rate country: a cross-sectional study in Russia. <i>Pharmacy Practice</i> , 2021, 19, 2276.	0.8	53
210	Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. <i>Vaccines</i> , 2021, 9, 296.	2.1	6
211	Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 181-186.	1.3	34

#	ARTICLE	IF	CITATIONS
213	Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays. <i>Diagnostics</i> , 2021, 11, 426.	1.3	31
214	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. <i>Nature Communications</i> , 2021, 12, 1403.	5.8	65
215	The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. <i>Viruses</i> , 2021, 13, 425.	1.5	27
216	Advances in gene-based vaccine platforms to address the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 113-141.	6.6	71
217	Precision therapeutic targets for COVID-19. <i>Virology Journal</i> , 2021, 18, 66.	1.4	40
218	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. <i>ACS Central Science</i> , 2021, 7, 512-533.	5.3	217
219	Interactions of SARS-CoV-2 with the Blood-Brain Barrier. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2681.	1.8	99
220	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. <i>Science Advances</i> , 2021, 7, .	4.7	100
221	BNT162b2 mRNA COVID-19 Vaccine: First Approval. <i>Drugs</i> , 2021, 81, 495-501.	4.9	232
224	Coronavirus disease 2019 (COVID-19) vaccination in healthcare workers: An early real-world experience. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-2.	1.0	3
225	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , 2021, 594, 253-258.	13.7	253
226	Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing. <i>Clinical Infectious Diseases</i> , 2022, 74, 294-300.	2.9	57
227	SARS-CoV-2 Seroprevalence in Healthcare Workers in Germany: A Follow-Up Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 4540.	1.2	11
230	Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). <i>Viruses</i> , 2021, 13, 756.	1.5	130
231	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. <i>Pharmaceuticals</i> , 2021, 14, 406.	1.7	101
233	Immunogenicity of the Ad26.COVS.2 Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
234	Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1037-1042.	2.2	266
236	Are vaccines against COVID-19 tailored to the most vulnerable people?. <i>Vaccine</i> , 2021, 39, 2325-2327.	1.7	19

#	ARTICLE	IF	CITATIONS
237	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
238	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 215-239.	6.6	66
239	No Time to Age: Uncoupling Aging from Chronological Time. <i>Genes</i> , 2021, 12, 611.	1.0	12
241	COVID-19 immunity and vaccines: what a pharmacist needs to know. <i>Asian Biomedicine</i> , 2021, 15, 51-67.	0.2	0
242	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2021, 137, 3165-3173.	0.6	539
243	Neutralizing Activity of BNT162b2-Elicited Serum. <i>New England Journal of Medicine</i> , 2021, 384, 1466-1468.	13.9	528
245	Strategies for Immunomonitoring after Vaccination and during Infection. <i>Vaccines</i> , 2021, 9, 365.	2.1	12
246	Considerations for bioanalytical characterization and batch release of COVID-19 vaccines. <i>Npj Vaccines</i> , 2021, 6, 53.	2.9	23
247	Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. <i>Journal of Pharmacy Practice</i> , 2022, 35, 947-951.	0.5	82
250	COVID-19 dynamics after a national immunization program in Israel. <i>Nature Medicine</i> , 2021, 27, 1055-1061.	15.2	183
251	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. <i>Nature Medicine</i> , 2021, 27, 1062-1070.	15.2	114
252	Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. <i>Vaccines</i> , 2021, 9, 360.	2.1	74
253	Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2065-2072.	2.9	409
254	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. <i>Science</i> , 2021, 372, 1418-1423.	6.0	286
255	Publications and retracted articles of COVID-19 pharmacotherapy-related research: A systematic review. <i>Science Progress</i> , 2021, 104, 003685042110169.	1.0	15
257	COVID-19 Vaccine in Veterans with Multiple Sclerosis: Protect the Vulnerable. , 2021, 38, S28-S32.		1
259	BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19. <i>Vaccines</i> , 2021, 9, 324.	2.1	14
262	mRNA-Based Vaccines. <i>Vaccines</i> , 2021, 9, 390.	2.1	67

#	ARTICLE	IF	CITATIONS
263	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 669339.	2.2	81
264	Promoting COVID-19 Vaccination on Social Media. <i>Pediatrics</i> , 2021, 147, .	1.0	7
265	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. <i>Immunological Investigations</i> , 2021, 50, 743-779.	1.0	16
266	Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1453-1462.	1.4	59
267	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021, 29, 529-539.e3.	5.1	324
268	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. <i>Transplantation</i> , 2021, 105, e94-e95.	0.5	105
269	Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. <i>Npj Vaccines</i> , 2021, 6, 65.	2.9	36
270	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. <i>ACS Nano</i> , 2021, 15, 5793-5818.	7.3	32
271	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2021, 32, 1219-1249.	1.9	19
272	The COVID-19 Vaccine in Clinical Trials: Where Are We Now?. <i>Infectious Diseases & Immunity</i> , 2021, 1, 43-51.	0.2	4
273	Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults. <i>Immunological Investigations</i> , 2021, 50, 810-820.	1.0	10
274	Acceptance of COVID-19 Vaccination among Front-Line Health Care Workers: A Nationwide Survey of Emergency Medical Services Personnel from Germany. <i>Vaccines</i> , 2021, 9, 424.	2.1	50
275	The impact of COVID-19 vaccination campaigns accounting for antibody-dependent enhancement. <i>PLoS ONE</i> , 2021, 16, e0245417.	1.1	10
276	Status Report on COVID-19 Vaccines Development. <i>Current Infectious Disease Reports</i> , 2021, 23, 9.	1.3	56
277	Practical handling of allergic reactions to COVID-19 vaccines. <i>Allergo Journal International</i> , 2021, 30, 79-95.	0.9	25
278	Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine. <i>British Journal of Ophthalmology</i> , 2021, 105, 893-896.	2.1	104
279	mRNA therapeutics in cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 69.	7.9	168
280	Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. <i>Blood</i> , 2021, 137, 3674-3676.	0.6	130

#	ARTICLE	IF	CITATIONS
281	SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2356-2366.	1.4	64
283	Inability to work after corona vaccination in medical staff. <i>Deutsches Ärzteblatt International</i> , 2021, 118, 298-299.	0.6	8
285	A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. <i>Cell</i> , 2021, 184, 2229-2238.e13.	13.5	51
286	Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. <i>Nature Communications</i> , 2021, 12, 2117.	5.8	70
288	SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. <i>Cell Host and Microbe</i> , 2021, 29, 522-528.e2.	5.1	173
289	Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets. <i>MBio</i> , 2021, 12, .	1.8	40
290	Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 153, 72-85.	0.9	12
291	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 4059-4066.	2.1	22
292	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. <i>Frontiers in Immunology</i> , 2021, 12, 656362.	2.2	29
293	Developing standard safety outcomes for COVID-19 vaccines. <i>Vaccine</i> , 2021, 39, 3025-3027.	1.7	3
295	Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines. <i>Pharmaceutics</i> , 2021, 13, 644.	2.0	17
297	Production of SARS-CoV-2 Virus-Like Particles in Insect Cells. <i>Vaccines</i> , 2021, 9, 554.	2.1	19
298	Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Naive Nursing Home Residents. <i>Clinical Infectious Diseases</i> , 2021, 73, 2112-2115.	2.9	69
300	Influenza Virus and SARS-CoV-2 Vaccines. <i>Journal of Immunology</i> , 2021, 206, 2509-2520.	0.4	11
304	Chemo-Enzymatic Modification of the 5' Cap Maintains Translation and Increases Immunogenic Properties of mRNA. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 13280-13286.	7.2	34
307	Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1784.	3.8	452
308	Development of COVID-19 Infection in Transplant Recipients After SARS-CoV-2 Vaccination. <i>Transplantation</i> , 2021, 105, e104-e106.	0.5	49
311	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 86.	6.9	31

#	ARTICLE	IF	CITATIONS
312	Promising Immunotherapies against COVID-19. <i>Advanced Therapeutics</i> , 2021, 4, 2100044.	1.6	4
313	Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV. <i>Aids</i> , 2021, 35, 1872-1874.	1.0	41
314	Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy. <i>Current Medicinal Chemistry</i> , 2022, 29, 635-665.	1.2	11
316	Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects. <i>Vaccines</i> , 2021, 9, 556.	2.1	140
317	Can reactogenicity predict immunogenicity after COVID-19 vaccination?. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1486-1491.	0.7	47
318	Preliminary evidence on the safety profile of BNT162b2 (<i>Comirnaty</i>): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2969-2971.	1.4	18
319	The COVID-19 Menace. <i>Global Challenges</i> , 2021, 5, 2100004.	1.8	5
320	COVID-19 vaccines: progress and understanding on quality control and evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 199.	7.1	21
321	COVID-19 in Solid Organ Transplantation: Disease Severity and Clinical Update. <i>Transplantation Proceedings</i> , 2021, 53, 1227-1236.	0.3	13
322	Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. <i>BMJ</i> , 2021, 373, n1088.	3.0	881
324	COVID-19: vaccine™s progress. <i>Microbial Biotechnology</i> , 2021, 14, 1246-1257.	2.0	16
326	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
327	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2021, 238, 569-578.	0.3	6
328	Eine chemoenzymatische Modifizierung der 5'â€²â€²Kappe erhÃlt die Translation und erhÃhrt die ImmunogenitÃt der mRNA. <i>Angewandte Chemie</i> , 2021, 133, 13390-13397.	1.6	2
329	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. <i>International Reviews of Immunology</i> , 2021, , 1-16.	1.5	6
330	Advances of nanomaterialsâ€based strategies for fighting against COVID-19. <i>View</i> , 2021, 2, 20200180.	2.7	16
331	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. <i>Lancet Infectious Diseases</i> , 2021, 21, 637-646.	4.6	326
332	High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1351-1352.	0.5	110

#	ARTICLE	IF	CITATIONS
334	In silico identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-16.	2.0	2
335	Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives. <i>World Journal of Clinical Cases</i> , 2021, 9, 2951-2968.	0.3	8
337	Coincidental SARS-CoV-2 infection and mRNA vaccination: a case report addressing the most important clinical questions. <i>Infection</i> , 2021, 49, 785-788.	2.3	0
338	Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. <i>Diagnostics</i> , 2021, 11, 869.	1.3	1
340	A network analysis of COVID-19 mRNA vaccine patents. <i>Nature Biotechnology</i> , 2021, 39, 546-548.	9.4	58
342	Immunogenicity of the <scp>BNT162b2 mRNA</scp> vaccine in heart transplant <scp>recipientsÂ€ˆÂa</scp> prospective cohort study. <i>European Journal of Heart Failure</i> , 2021, 23, 1555-1559.	2.9	71
343	A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 213.	7.1	76
344	The dawn of mRNA vaccines: The COVID-19 case. <i>Journal of Controlled Release</i> , 2021, 333, 511-520.	4.8	276
345	Harnessing Natural Mosaics: Antibody-Instructed, Multi-Envelope HIV-1 Vaccine Design. <i>Viruses</i> , 2021, 13, 884.	1.5	1
346	Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. <i>Npj Vaccines</i> , 2021, 6, 74.	2.9	198
348	Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries. <i>Annals of Medicine and Surgery</i> , 2021, 65, 102264.	0.5	19
350	Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2204.	3.8	835
351	COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says. <i>Frontiers in Immunology</i> , 2021, 12, 669010.	2.2	31
354	Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein. <i>Journal of Immunology</i> , 2021, 206, 2596-2604.	0.4	4
355	Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases. <i>Immunological Investigations</i> , 2021, 50, 833-856.	1.0	3
356	The safety of Covid-19 mRNA vaccines: a review. <i>Patient Safety in Surgery</i> , 2021, 15, 20.	1.1	150
357	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
358	High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1704-1709.	0.4	87

#	ARTICLE	IF	CITATIONS
359	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. <i>Human Genomics</i> , 2021, 15, 27.	1.4	39
360	Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2913-2915.	2.6	112
361	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Vaccines</i> , 2021, 9, 467.	2.1	228
362	Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1339-1344.	0.5	202
363	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. <i>Nature</i> , 2021, 595, 572-577.	13.7	583
364	Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. <i>American Journal of Transplantation</i> , 2021, 21, 2719-2726.	2.6	317
365	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 1205-1211.	15.2	3,133
366	Gastroparesis After Pfizer-BioNTech COVID-19 Vaccination. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, 2300.	0.2	5
368	Future considerations for the mRNA-lipid nanoparticle vaccine platform. <i>Current Opinion in Virology</i> , 2021, 48, 65-72.	2.6	63
369	Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers. <i>EClinicalMedicine</i> , 2021, 36, 100914.	3.2	22
370	Lipophilic Polyamines as Promising Components of Liposomal Gene Delivery Systems. <i>Pharmaceutics</i> , 2021, 13, 920.	2.0	9
372	Review: Vaccine Myth-Buster – Cleaning Up With Prejudices and Dangerous Misinformation. <i>Frontiers in Immunology</i> , 2021, 12, 663280.	2.2	22
374	Special Focus Issue - Applications of nanotechnology against COVID-19: a special focus issue by Nanomedicine. <i>Nanomedicine</i> , 2021, 16, 1177-1178.	1.7	1
375	COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. <i>Journal of Infectious Diseases</i> , 2021, 224, 793-797.	1.9	30
377	Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization. <i>AAPS PharmSciTech</i> , 2021, 22, 172.	1.5	24
379	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. <i>Canadian Journal of Physiology and Pharmacology</i> , 2021, 99, 577-588.	0.7	2
380	B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1672-1677.	2.8	26
381	Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cells recipients. <i>EJHaem</i> , 2021, 2, 520-524.	0.4	28

#	ARTICLE	IF	CITATIONS
383	COVID-19 vaccination in pediatric solid organ transplant recipients—Current state and future directions. <i>Pediatric Transplantation</i> , 2021, 25, e14031.	0.5	4
384	Adenovirus and RNA-based COVID-19 vaccines™ perceptions and acceptance among healthcare workers in Saudi Arabia: a national survey. <i>BMJ Open</i> , 2021, 11, e048586.	0.8	31
385	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
386	Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination. <i>Human Gene Therapy</i> , 2021, 32, 541-562.	1.4	9
387	One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	94
388	Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2147-2152.	3.0	155
389	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. <i>ACS Central Science</i> , 2021, 7, 1191-1204.	5.3	34
390	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. <i>Advances in Molecular Pathology</i> , 2021, , .	0.2	1
391	COVID-19 vaccines: Frequently asked questions and updated answers. <i>Infectious Diseases Now</i> , 2021, 51, 319-333.	0.7	10
392	Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. <i>Bioactive Materials</i> , 2022, 9, 590-601.	8.6	33
393	Quantitative SARS-CoV-2 anti-spike responses to Pfizer—BioNTech and Oxford—AstraZeneca vaccines by previous infection status. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1516.e7-1516.e14.	2.8	100
394	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	13.7	549
396	Clinical consequences of the suboptimal effect of messenger RNA-based SARS-CoV-2 vaccine in renal transplant recipients. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 248-249.	0.4	3
397	Gene therapy avenues and COVID-19 vaccines. <i>Genes and Immunity</i> , 2021, 22, 120-124.	2.2	18
398	The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2). <i>BioMed Research International</i> , 2021, 2021, 1-20.	0.9	13
399	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 701752.	2.2	17
400	First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	116
401	Association of Simulated COVID-19 Vaccination and Nonpharmaceutical Interventions With Infections, Hospitalizations, and Mortality. <i>JAMA Network Open</i> , 2021, 4, e2110782.	2.8	90

#	ARTICLE	IF	CITATIONS
402	Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2075-2082.e2.	1.5	117
403	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. <i>Frontiers in Immunology</i> , 2021, 12, 690698.	2.2	52
404	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3546-3567.	2.0	152
406	Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies. <i>Scientific Reports</i> , 2021, 11, 13120.	1.6	11
407	Hypotheses: implementation of Le Chatelier's principle as a potential integrative method to prevent and or cure coronavirus. <i>Journal of Public Health and Emergency</i> , 0, 5, 17-17.	4.4	0
408	Specific Treatment Exists for SARS-CoV-2 ARDS. <i>Vaccines</i> , 2021, 9, 635.	2.1	11
409	Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1754-1755.	0.4	10
410	Postvaccine Anti-SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 1699-1700.	0.4	37
411	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15
412	Updates on the coronavirus disease 2019 vaccine and consideration in children. <i>Clinical and Experimental Pediatrics</i> , 2021, 64, 328-338.	0.9	8
413	How has nanomedical innovation contributed to the COVID-19 vaccine development?. <i>Nanomedicine</i> , 2021, 16, 1179-1181.	1.7	11
414	Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses. <i>ACS Nano</i> , 2021, 15, 11180-11191.	7.3	60
415	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. <i>International Journal of Pharmaceutics</i> , 2021, 603, 120686.	2.6	83
416	Toward the prevention of coronavirus infection: what role can polymers play?. <i>Materials Today Advances</i> , 2021, 10, 100140.	2.5	18
417	Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. <i>Lancet Rheumatology</i> , The, 2021, 3, e470-e472.	2.2	44
418	Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. <i>Lancet Haematology</i> , the, 2021, 8, e389-e392.	2.2	121
419	Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI. <i>Vaccines</i> , 2021, 9, 685.	2.1	43
422	The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe. <i>Covid</i> , 2021, 1, 20-38.	0.7	22

#	ARTICLE	IF	CITATIONS
424	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. <i>Science Immunology</i> , 2021, 6, .	5.6	34
425	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. <i>Virology</i> , 2021, 558, 1-12.	1.1	17
426	Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: No cause for alarm. <i>American Journal of Transplantation</i> , 2021, 21, 2908.	2.6	4
427	Improving kidney targeting: The influence of nanoparticle physicochemical properties on kidney interactions. <i>Journal of Controlled Release</i> , 2021, 334, 127-137.	4.8	63
428	Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. <i>Lancet Respiratory Medicine</i> , 2021, 9, e52-e53.	5.2	60
429	Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. <i>Briefings in Functional Genomics</i> , 2021, 20, 289-303.	1.3	16
432	Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization. <i>JAMA Network Open</i> , 2021, 4, e2115985.	2.8	96
433	Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 691715.	2.2	76
434	Myocarditis following COVID-19 mRNA vaccination. <i>Vaccine</i> , 2021, 39, 3790-3793.	1.7	215
435	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.	13.7	318
437	Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay. <i>Vaccines</i> , 2021, 9, 611.	2.1	5
438	Subjective Feelings of Polish Doctors after Receiving the COVID-19 Vaccine. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6291.	1.2	11
439	Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 754-764.	1.8	5
440	Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome. <i>Cells</i> , 2021, 10, 1412.	1.8	6
442	Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2. <i>BMC Infectious Diseases</i> , 2021, 21, 580.	1.3	20
443	An intra-host SARS-CoV-2 dynamics model to assess testing and quarantine strategies for incoming travelers, contact management, and de-isolation. <i>Patterns</i> , 2021, 2, 100262.	3.1	15
445	A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. <i>Molecular Therapy</i> , 2021, 29, 1970-1983.	3.7	111
446	Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021, 185, 646-648.	1.4	30

#	ARTICLE	IF	CITATIONS
447	Role of nanotechnology behind the success of mRNA vaccines for COVID-19. <i>Nano Today</i> , 2021, 38, 101142.	6.2	170
448	Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis. <i>Vaccines</i> , 2021, 9, 582.	2.1	65
449	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. <i>Kidney International</i> , 2021, 99, 1470-1477.	2.6	58
450	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	64
451	Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. <i>EClinicalMedicine</i> , 2021, 36, 100928.	3.2	135
452	Human IgG and IgA responses to COVID-19 mRNA vaccines. <i>PLoS ONE</i> , 2021, 16, e0249499.	1.1	148
453	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 803-812.	4.6	415
454	Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2153-2158.	3.0	140
455	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. <i>Nature Medicine</i> , 2021, 27, 1379-1384.	15.2	296
456	Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. <i>Cell Host and Microbe</i> , 2021, 29, 917-929.e4.	5.1	132
457	COVID-19 vaccination and IgG and IgA antibody dynamics in healthcare workers. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	33
458	A public health perspective on mental health: lessons for population health in the 21st century. <i>Irish Journal of Psychological Medicine</i> , 2021, , 1-4.	0.7	0
459	Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers. <i>Journal of Virus Eradication</i> , 2021, 7, 100046.	0.3	13
460	Using cross-species vaccination approaches to counter emerging infectious diseases. <i>Nature Reviews Immunology</i> , 2021, 21, 815-822.	10.6	17
461	Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1635-1638.	0.5	55
462	Therapeutic vaccine for chronic diseases after the COVID-19 Era. <i>Hypertension Research</i> , 2021, 44, 1047-1053.	1.5	7
463	The Safety of COVID-19 Vaccinations – We Should Rethink the Policy. <i>Vaccines</i> , 2021, 9, 693.	2.1	23
464	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241

#	ARTICLE	IF	CITATIONS
466	SARS-CoV-2 Antiviral Therapy. <i>Clinical Microbiology Reviews</i> , 2021, 34, e0010921.	5.7	64
467	SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo��. <i>Nature Communications</i> , 2021, 12, 4383.	5.8	33
469	SARS-CoV-2 vaccination in cardiothoracic organ transplant recipients: effective strategies wanted. <i>Clinical Research in Cardiology</i> , 2021, 110, 1139-1141.	1.5	0
470	Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2022, 23, 233-250.	2.6	13
471	Asymptomatic COVID-19 cases among older patients despite BNT162b2 vaccination: A case series in a geriatric rehabilitation ward during an outbreak. <i>Journal of Infection</i> , 2021, 83, 119-145.	1.7	4
472	The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study. <i>Clinical and Experimental Nephrology</i> , 2021, 26, 54.	0.7	3
474	How to interpret and use COVID-19 serology and immunology tests. <i>Clinical Microbiology and Infection</i> , 2021, 27, 981-986.	2.8	94
475	Personalized health and the coronavirus vaccines��Do��individual genetics matter?. <i>BioEssays</i> , 2021, 43, e2100087.	1.2	9
477	SARS-CoV-2 anti-nucleocapsid assay performance in healthcare workers at baseline and 6��months. <i>Irish Journal of Medical Science</i> , 2022, 191, 1089-1092.	0.8	7
478	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. <i>BMC Medicine</i> , 2021, 19, 173.	2.3	156
479	Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1654-1664.	4.6	200
481	Plasma cell biology: Foundations for targeted therapeutic development in transplantation. <i>Immunological Reviews</i> , 2021, 303, 168-186.	2.8	3
483	SARS-CoV-2 serology testing: Progress and challenges. <i>Journal of Immunological Methods</i> , 2021, 494, 113060.	0.6	21
484	Individual HLA-A, -B, -C, and -DRB1 Genotypes Are No Major Factors Which Determine COVID-19 Severity. <i>Frontiers in Immunology</i> , 2021, 12, 698193.	2.2	15
485	Din��mica y relaci��n del contagio del COVID-19 despu��s de iniciado el plan de vacunaci��n contra el SARS-COV-2 en Colombia. <i>Repertorio De Medicina Y Cirug��a</i> , 0, , 41-45.	0.0	3
486	COVID-19 vaccines: concerns beyond protective efficacy and safety. <i>Expert Review of Vaccines</i> , 2021, 20, 1013-1025.	2.0	56
487	Covid-19 Vaccine Benefits and Concerns: Nigerian Perspectives. <i>Journal of Clinical and Medical Research</i> , 0, , .	0.0	0
488	Early approval of COVID-19 vaccines: Pros and cons. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3288-3296.	1.4	14

#	ARTICLE	IF	CITATIONS
489	Cross-Reactive Immune Responses toward the Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study. <i>Microorganisms</i> , 2021, 9, 1643.	1.6	19
491	Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity. <i>Cells</i> , 2021, 10, 1756.	1.8	19
492	Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 742.	2.1	39
493	Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. <i>Infectious Diseases of Poverty</i> , 2021, 10, 94.	1.5	109
494	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 239-250.	13.9	709
495	Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC50) of neutralizing antibodies. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1063-1067.	0.8	9
496	Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103028.	0.9	20
497	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. <i>Vaccines</i> , 2021, 9, 781.	2.1	28
498	Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol. <i>Pathogens</i> , 2021, 10, 911.	1.2	6
500	Human Coronaviruses: Counteracting the Damage by Storm. <i>Viruses</i> , 2021, 13, 1457.	1.5	5
501	COVID-19: Perceived Infection Risk and Barriers to Uptake of Pfizer-BioNTech and Moderna Vaccines Among Community Healthcare Workers. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, 9, 1543-1549.	1.8	14
502	Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. <i>Frontiers in Immunology</i> , 2021, 12, 669357.	2.2	7
504	Safety, efficacy and acceptability of SARS-CoV-2 vaccines in patients with cancer. <i>Future Virology</i> , 2021, 16, 443-446.	0.9	3
505	Predictive Analytics of COVID-19 with Neural Networks. , 2021, , .		7
506	Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2021, 356, 577599.	1.1	62
507	Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2234-2238.	1.4	17
508	Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. <i>Aids</i> , 2021, 35, 2399-2401.	1.0	76
509	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 950-961.	4.6	271

#	ARTICLE	IF	CITATIONS
510	Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. <i>Leukemia</i> , 2021, 35, 3534-3541.	3.3	71
511	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
515	High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events. <i>Vaccines</i> , 2021, 9, 712.	2.1	25
518	Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 271.	7.1	25
519	Navigating post-vaccine COVID-19 futures in the health and economic context. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 893-894.	4.6	3
520	Efficacy of COVID-19 vaccines: From clinical trials to real life. <i>Therapie</i> , 2021, 76, 277-283.	0.6	30
523	Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2021, 3, 622-628.	0.9	67
524	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , 2021, 36, 109353.	2.9	95
525	<sc>BNT162b2 COVID</sc> vaccine is significantly less effective in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2021, 96, 1195-1203.	2.0	142
526	Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine. <i>Clinical and Experimental Medicine</i> , 2022, 22, 319-323.	1.9	30
527	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	56
528	Virus Induced Lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics. <i>Scientific Reports</i> , 2021, 11, 15295.	1.6	5
529	Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant. <i>Vaccines</i> , 2021, 9, 737.	2.1	5
530	A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples. <i>Scientific Reports</i> , 2021, 11, 15321.	1.6	33
531	The battle of testing in COVID-19: the secrets of victory against the virus. <i>Cardiovascular Research</i> , 2021, 117, e101-e103.	1.8	0
532	Prevention and management of infections after exposure to ionizing radiation. <i>Journal of Radiological Protection</i> , 2021, 41, .	0.6	1
533	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 281-294.	0.4	4
534	Reply: Vascularized Composite Allotransplantation in a Post-COVID-19 Pandemic World. <i>Plastic and Reconstructive Surgery</i> , 2021, 148, 317e-318e.	0.7	1

#	ARTICLE	IF	CITATIONS
535	Efficacy of the COVID-19 vaccine in heart transplant recipients: what we know and what we ignore. <i>European Journal of Heart Failure</i> , 2021, 23, 1560-1562.	2.9	3
536	Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines. <i>Small Methods</i> , 2021, 5, 2100402.	4.6	45
537	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. <i>Biomedicines</i> , 2021, 9, 903.	1.4	5
538	From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape. <i>Frontiers in Immunology</i> , 2021, 12, 679344.	2.2	74
539	Multisystem inflammatory syndrome in an adult following the SARS-CoV-2 vaccine (MIS-V). <i>BMJ Case Reports</i> , 2021, 14, e243888.	0.2	83
540	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. <i>International Immunopharmacology</i> , 2021, 96, 107763.	1.7	35
542	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	13.5	241
543	Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. <i>Clinical Research in Cardiology</i> , 2021, 110, 1142-1149.	1.5	70
544	Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. <i>JAMA Oncology</i> , 2021, 7, 1507.	3.4	131
546	Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. <i>Cell Research</i> , 2021, 31, 1011-1023.	5.7	48
547	BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine. <i>American Journal of Case Reports</i> , 2021, 22, e933003.	0.3	1
549	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88
550	CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines In Vitro. <i>Frontiers in Immunology</i> , 2021, 12, 652223.	2.2	27
551	BNT 13b2 Pfizer vaccine protects against SARS-CoV-2 respiratory mucosal colonization even after prolonged exposure to positive family members. <i>Journal of Hospital Infection</i> , 2021, 113, 192-194.	1.4	0
553	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
554	COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. <i>Cancers</i> , 2021, 13, 3573.	1.7	39
555	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0254734.	1.1	12
556	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. <i>HemaSphere</i> , 2021, 5, e614.	1.2	7

#	ARTICLE	IF	CITATIONS
559	Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers. <i>Cells</i> , 2021, 10, 1942.	1.8	38
560	Humoral Response to SARS-Cov-2 Vaccination in Liver Transplant Recipientsâ€“A Single-Center Experience. <i>Vaccines</i> , 2021, 9, 738.	2.1	54
561	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
562	Evidence for antibody as a protective correlate for COVID-19 vaccines. <i>Vaccine</i> , 2021, 39, 4423-4428.	1.7	766
563	Lipids and Lipid Derivatives for RNA Delivery. <i>Chemical Reviews</i> , 2021, 121, 12181-12277.	23.0	227
564	Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies. <i>Transplantation</i> , 2021, 105, e234-e243.	0.5	39
565	Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Vaccines</i> , 2021, 9, 939.	2.1	25
566	Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients. <i>JAAD Case Reports</i> , 2021, 14, 13-16.	0.4	10
567	Higher severity and risk of in-hospital mortality for COVID-19 patients with cancer during the year 2020 in Brazil: A countrywide analysis of secondary data. <i>Cancer</i> , 2021, 127, 4240-4248.	2.0	12
568	Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies. <i>Blood Cancer Journal</i> , 2021, 11, 142.	2.8	106
569	Lessons Learnt From the COVID-19 Pandemic. <i>Frontiers in Public Health</i> , 2021, 9, 694705.	1.3	24
571	Wastewater Surveillance during Mass COVID-19 Vaccination on a College Campus. <i>Environmental Science and Technology Letters</i> , 2021, 8, 792-798.	3.9	45
572	Putative Role of Vitamin D for COVID-19 Vaccination. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8988.	1.8	32
573	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40
574	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 910.	2.1	50
575	Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. <i>Reproductive Toxicology</i> , 2021, 103, 28-35.	1.3	50
576	Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. <i>EClinicalMedicine</i> , 2021, 38, 100989.	3.2	56
577	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1107-1119.	4.6	345

#	ARTICLE	IF	CITATIONS
578	An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. <i>Vaccine</i> , 2021, 39, 4988-5001.	1.7	26
579	Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2022, 114, 203-209.	3.0	65
580	Significant Publications on Infectious Diseases Pharmacotherapy in 2020. <i>Journal of Pharmacy Practice</i> , 2023, 36, 394-406.	0.5	1
581	Potential for Developing Plant-Derived Candidate Vaccines and Biologics against Emerging Coronavirus Infections. <i>Pathogens</i> , 2021, 10, 1051.	1.2	18
582	Systematic profiling of SARS-CoV-2-specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins for predicting vaccination efficacy. <i>Cell Discovery</i> , 2021, 7, 67.	3.1	29
583	In Vitro Investigations on Optimizing and Nebulization of IVT-mRNA Formulations for Potential Pulmonary-Based Alpha-1-Antitrypsin Deficiency Treatment. <i>Pharmaceutics</i> , 2021, 13, 1281.	2.0	7
584	Nanoparticles in the clinic: An update post COVID-19 vaccines. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10246.	3.9	173
585	Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. <i>Journal of Infection</i> , 2021, 83, 237-279.	1.7	56
587	COVID 19 and vaccine safety. <i>Journal of Education, Health and Sport</i> , 2021, 11, 313-321.	0.0	0
589	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. <i>EClinicalMedicine</i> , 2021, 38, 101010.	3.2	28
590	SARS-CoV-2 messenger RNA vaccine antibody response and reactogenicity in heart and lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1579-1588.	0.3	52
591	Vaccine delivery systems toward lymph nodes. <i>Advanced Drug Delivery Reviews</i> , 2021, 179, 113914.	6.6	62
592	Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. <i>Nature Nanotechnology</i> , 2021, 16, 843-850.	15.6	40
595	Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort. <i>Lancet Rheumatology</i> , The, 2021, 3, e585-e594.	2.2	18
596	Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection. <i>Nutrients</i> , 2021, 13, 2800.	1.7	67
597	Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3053-3061.	2.5	123
598	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
599	Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. <i>JAMA Oncology</i> , 2021, 7, 1714.	3.4	63

#	ARTICLE	IF	CITATIONS
600	Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. <i>New England Journal of Medicine</i> , 2021, 385, 2241-2251.	13.9	267
601	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. <i>Vaccines</i> , 2021, 9, 869.	2.1	17
603	Immunogenicity of BNT162b2 SARS-CoV-2 Vaccine in a Multicenter Cohort of Nursing Home Residents Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2021, 78, 766-768.	2.1	14
604	Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1535-1537.	1.4	8
605	Specific approaches to patients affected by dementia and covid-19 in nursing homes: the role of the geriatrician. <i>Ageing Research Reviews</i> , 2021, 69, 101373.	5.0	9
606	Case Report: Severe COVID-19 in a Kidney Transplant Recipient Without Humoral Response to SARS-CoV-2 mRNA Vaccine Series. <i>Transplantation Direct</i> , 2021, 7, e743.	0.8	3
607	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. <i>Cells</i> , 2021, 10, 2212.	1.8	4
608	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104869.	1.0	49
610	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <i>Current Opinion in Virology</i> , 2021, 49, 127-138.	2.6	2
611	An Update on mRNA-Based Viral Vaccines. <i>Vaccines</i> , 2021, 9, 965.	2.1	14
612	Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1861.e1-1861.e5.	2.8	107
613	Analytical techniques currently used in the pharmaceutical industry for the quality control of RNA-based therapeutics and ongoing developments. <i>Journal of Chromatography A</i> , 2021, 1651, 462283.	1.8	12
614	Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNeâ€”short- And long-term Immune reSponSe evALuatioN in health Care workErs. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2966-2979.	1.4	18
615	LIVEITIS AFTER THE BNT162b2 mRNA VACCINATION AGAINST SARS-CoV-2 INFECTION. <i>Retina</i> , 2021, 41, 2462-2471.	1.0	86
616	Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2021, 78, 314-317.	2.1	34
617	Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. <i>Cancer Cell</i> , 2021, 39, 1031-1033.	7.7	219
618	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. <i>Pathogens</i> , 2021, 10, 1030.	1.2	33
619	Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers. <i>Journal of Medical Microbiology</i> , 2021, 70, .	0.7	10

#	ARTICLE	IF	CITATIONS
620	Systemic IL-15, IFN- β , and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. <i>Cell Reports</i> , 2021, 36, 109504.	2.9	137
621	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021, 373, 991-998.	6.0	144
622	Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. <i>Immunologic Research</i> , 2021, 69, 576-583.	1.3	34
623	Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA. <i>Cell Chemical Biology</i> , 2022, 29, 312-320.e7.	2.5	14
624	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. <i>EBioMedicine</i> , 2021, 70, 103539.	2.7	67
625	Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis. <i>Annals of Internal Medicine</i> , 2021, 174, 1073-1080.	2.0	21
626	Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. <i>Clinica Chimica Acta</i> , 2021, 519, 60-63.	0.5	74
627	Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients. <i>Transplantation</i> , 2021, 105, e226-e233.	0.5	46
628	Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3459-3476.	1.1	179
630	Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations. <i>Biologia (Poland)</i> , 2021, 76, 3465-3476.	0.8	6
631	Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. <i>Cancers</i> , 2021, 13, 4191.	1.7	34
632	Qualitative Assessment of Early Adverse Effects of Pfizer's BioNTech and Sinopharm COVID-19 Vaccines by Telephone Interviews. <i>Vaccines</i> , 2021, 9, 950.	2.1	18
633	Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. <i>Cell Discovery</i> , 2021, 7, 65.	3.1	51
634	Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding. <i>Cell Reports</i> , 2021, 36, 109493.	2.9	46
635	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 817-838.	21.5	577
636	An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines. <i>Journal of Clinical Medicine</i> , 2021, 10, 3817.	1.0	16
637	COMPUTER SIMULATION IN THE DEVELOPMENT OF VACCINES AGAINST COVID-19 BASED ON HLA-SYSTEM ANTIGENS. <i>Journal of Clinical Practice</i> , 0, , .	0.2	0
639	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1851-1855.	2.8	137

#	ARTICLE	IF	CITATIONS
641	Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1255-1265.	5.2	279
642	Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3971-3979.	2.6	85
644	Should Patient with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) be vaccinated with COVID-19 Vaccines?. <i>Indonesian Journal of Rheumatology</i> , 2021, 13, 492-503.	0.1	0
645	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. <i>Emerging Infectious Diseases</i> , 2021, 27, 2174-2178.	2.0	67
647	Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1130-1133.	1.3	13
648	Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine. <i>Vaccine</i> , 2021, 39, 5087-5090.	1.7	28
649	The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. <i>Blood Cancer Journal</i> , 2021, 11, 138.	2.8	103
650	Should nurses take a COVID-19 vaccine?. <i>Nursing Outlook</i> , 2021, 69, 1081-1089.	1.5	5
651	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2021, 9, 848.	2.1	64
652	Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.. <i>EClinicalMedicine</i> , 2021, 38, 101018.	3.2	77
653	Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2727-2739.	2.6	197
654	Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 3980-3989.	2.6	120
655	Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report. <i>International Journal of Infectious Diseases</i> , 2021, 110, 229-231.	1.5	15
657	Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. <i>British Journal of Haematology</i> , 2022, 196, 360-362.	1.2	24
658	Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients. <i>Scientific Reports</i> , 2021, 11, 17642.	1.6	41
661	Microfluidics for Development of Lipid Nanoparticles: Paving the Way for Nucleic Acids to the Clinic. <i>ACS Applied Bio Materials</i> , 2023, 6, 3566-3576.	2.3	18
662	Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study. <i>Cancers</i> , 2021, 13, 4480.	1.7	44
664	Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine. <i>British Journal of Haematology</i> , 2022, 196, 356-359.	1.2	18

#	ARTICLE	IF	CITATIONS
666	Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study. <i>Blood Advances</i> , 2021, 5, 4398-4405.	2.5	39
667	Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination. <i>Infectious Diseases</i> , 2022, 54, 63-71.	1.4	17
668	Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 3094-3096.	1.3	28
669	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
670	Adverse events and preventive measures related to COVID-19 vaccines. <i>Clinical and Experimental Emergency Medicine</i> , 2021, 8, 153-159.	0.5	1
671	Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation. <i>Nature Communications</i> , 2021, 12, 5333.	5.8	64
672	COVID-19 Vaccines: Current Conditions and Future Prospects. <i>Biology</i> , 2021, 10, 960.	1.3	14
673	Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study. <i>European Journal of Cancer</i> , 2021, 154, 167-174.	1.3	15
674	Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer. <i>European Journal of Cancer</i> , 2021, 154, 66-72.	1.3	31
675	Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). <i>Clinical Microbiology and Infection</i> , 2021, 27, 1351.e5-1351.e7.	2.8	54
676	IgG Antibodies Generation and Side Effects Caused by Ad5-nCoV Vaccine (CanSino Biologics) and BNT162b2 Vaccine (Pfizer/BioNTech) among Mexican Population. <i>Vaccines</i> , 2021, 9, 999.	2.1	23
677	The temporal course of T- and B-cell-responses to vaccination with BNT162b2 and mRNA-1273. <i>Clinical Microbiology and Infection</i> , 2021, , .	2.8	22
678	How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream. <i>Pharmaceutical Medicine</i> , 2021, 35, 287-295.	1.0	1
679	Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	14
681	Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 130-134.	2.8	48
682	Would Older Adults Perform Preventive Practices in the Post-COVID-19 Era? A Community-Based Cross-Sectional Survey in China. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10169.	1.2	0
683	Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. <i>PLoS ONE</i> , 2021, 16, e0257668.	1.1	33
684	Liposome interaction with macrophages and foam cells for atherosclerosis treatment: effects of size, surface charge and lipid composition. <i>Nanotechnology</i> , 2021, 32, 505105.	1.3	17

#	ARTICLE	IF	CITATIONS
685	SARS-CoV-2 infection shortly after BNT162b2 vaccination results in high anti-spike antibody levels in nursing home residents and staff. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1702-1706.	1.3	15
686	Bodily Distress Syndrome After Routine Vaccination: A Case Report. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2021, 62, 557-558.	0.2	3
687	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, eabj0847.	5.8	40
688	BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. <i>Lancet Respiratory Medicine</i> , 2021, 9, 999-1009.	5.2	279
689	Re: The first report on coronavirus disease 2019 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey. <i>European Journal of Cancer</i> , 2021, 158, 251-252.	1.3	4
690	5 reasons to encourage anti-SARS-CoV-2 vaccination in patients with rheumatic diseases. <i>Expert Review of Clinical Immunology</i> , 2021, , 1-4.	1.3	1
692	Nucleic acid delivery and nanoparticle design for COVID vaccines. <i>MRS Bulletin</i> , 2021, 46, 832-839.	1.7	12
693	SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans. <i>Frontiers in Immunology</i> , 2021, 12, 728021.	2.2	20
694	Immune Responses against SARS-CoV-2—Questions and Experiences. <i>Biomedicines</i> , 2021, 9, 1342.	1.4	10
695	Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 113, 233-235.	1.5	27
697	A Peptide-Based Assay Discriminates Individual Antibody Response to the COVID-19 Pfizer/BioNTech mRNA Vaccine. <i>Vaccines</i> , 2021, 9, 987.	2.1	2
698	Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. <i>Molecular and Cellular Toxicology</i> , 2022, 18, 1-8.	0.8	73
699	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 301.e1-301.e8.	2.8	28
700	Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD. <i>Kidney International Reports</i> , 2021, 6, 2292-2304.	0.4	96
701	Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. <i>Medicina (Lithuania)</i> , 2021, 57, 997.	0.8	9
702	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 973-987.	0.6	25
703	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
704	Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults. <i>Clinical Microbiology and Infection</i> , 2022, 28, 139.e1-139.e4.	2.8	29

#	ARTICLE	IF	CITATIONS
705	Comparison of hospitalizations and deaths from COVID-19 2021 versus 2020 in Italy: surprises and implications. <i>F1000Research</i> , 2021, 10, 964.	0.8	2
706	SARS-CoV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021, 39, 5769-5779.	1.7	23
707	Family Physicians' Perception of the New mRNA COVID-19 Vaccines. <i>Journal of the American Board of Family Medicine</i> , 2021, 34, 898-906.	0.8	8
708	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
709	Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2. <i>Journal of Clinical Medicine</i> , 2021, 10, 4204.	1.0	8
710	Validation of the effectiveness of SARS-CoV-2 vaccines in older adults in "real-world" settings. <i>Immunity and Ageing</i> , 2021, 18, 36.	1.8	6
712	Pattern Recognition Proteins: First Line of Defense Against Coronaviruses. <i>Frontiers in Immunology</i> , 2021, 12, 652252.	2.2	13
714	Clinical trial research on COVID-19 in Germany " a systematic analysis. <i>F1000Research</i> , 0, 10, 913.	0.8	5
715	Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113889.	6.6	48
716	Safety and Side Effects of COVID-19 Vaccines. <i>Journal of Education, Health and Sport</i> , 2021, 11, 315-320.	0.0	0
717	SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19. <i>IScience</i> , 2021, 24, 103185.	1.9	13
718	Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study. <i>Vaccine</i> , 2021, 39, 6535-6538.	1.7	30
719	SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays. <i>Microbiology Spectrum</i> , 2021, 9, e0039121.	1.2	17
720	Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. <i>New England Journal of Medicine</i> , 2021, 385, 1393-1400.	13.9	979
721	Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers. <i>International Journal of Infectious Diseases</i> , 2021, 113, 1-6.	1.5	11
722	Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients. <i>Pediatric Nephrology</i> , 2022, 37, 449-453.	0.9	34
723	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
724	Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics. <i>Journal of Personalized Medicine</i> , 2021, 11, 886.	1.1	17

#	ARTICLE	IF	CITATIONS
726	Management of inflammatory bowel disease during the COVID-19 pandemic. <i>Immunological Medicine</i> , 2022, 45, 128-135.	1.4	4
727	Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. <i>JCI Insight</i> , 2021, 6, .	2.3	18
728	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	89
729	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. <i>PLoS ONE</i> , 2021, 16, e0257191.	1.1	19
733	Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal?. <i>International Journal of Infectious Diseases</i> , 2021, 110, 258-260.	1.5	9
734	Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009701.	2.1	12
735	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
736	Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. <i>European Journal of Immunology</i> , 2021, 51, 3202-3213.	1.6	76
737	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. <i>Vaccines</i> , 2021, 9, 1082.	2.1	8
738	Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e783-e791.	2.9	71
740	Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine. <i>Clinical Transplantation</i> , 2021, 35, e14478.	0.8	28
741	Nucleic acid delivery for therapeutic applications. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113834.	6.6	122
742	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 708848.	2.2	7
743	Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2021, 4, e2126344.	2.8	55
744	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. <i>Microbiology Spectrum</i> , 2021, 9, e0034121.	1.2	114
745	Antibody Response to Severe Acute Respiratory Syndrome-Coronavirus-2 Messenger RNA Vaccines in Liver Transplant Recipients. <i>Liver Transplantation</i> , 2021, 27, 1852-1856.	1.3	55
746	Synthetic modified messenger RNA for therapeutic applications. <i>Acta Biomaterialia</i> , 2021, 131, 1-15.	4.1	34
747	COVID-19 Vaccination in Pregnancy and Lactation: Current Research and Gaps in Understanding. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 735394.	1.8	35

#	ARTICLE	IF	CITATIONS
748	Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines. PLoS ONE, 2021, 16, e0252849.	1.1	11
749	Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 3990-4002.	2.6	124
750	Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥ 16 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, September 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1344-1348.	9.0	29
751	Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatology International, 2021, 41, 1925-1931.	1.5	41
752	Recent advances and developments in COVID-19 in the context of allergic diseases. Clinical and Translational Allergy, 2021, 11, e12065.	1.4	7
753	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 2021, 385, 1761-1773.	13.9	1,090
754	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. International Journal of Biological Macromolecules, 2021, 188, 740-750.	3.6	83
755	A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open, 2021, 6, 100272.	2.0	34
756	Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. Biomedicine and Pharmacotherapy, 2021, 142, 111953.	2.5	64
757	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. Journal of Biological Chemistry, 2021, 297, 101127.	1.6	9
758	Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. American Journal of Kidney Diseases, 2021, 78, 571-581.	2.1	100
759	Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2022, 28, 1126-1130.	1.4	7
760	Animal models of SARS-CoV-2 transmission. Current Opinion in Virology, 2021, 50, 8-16.	2.6	21
762	COVID-19 in Children. Pediatric Clinics of North America, 2021, 68, 961-976.	0.9	21
763	Administration of COVID-19 vaccines in immunocompromised patients. International Immunopharmacology, 2021, 99, 108021.	1.7	51
764	Herpes Zoster Following the COVID-19 Vaccination in Breast Cancer Long Time Survivor Patients. Cureus, 2021, 13, e18418.	0.2	5
765	Serological response to a single dose of a SARS-CoV-2 mRNA vaccine. Journal of Virological Methods, 2021, 296, 114223.	1.0	5
766	Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain. Emerging Infectious Diseases, 2021, 27, 2595-2603.	2.0	39

#	ARTICLE	IF	CITATIONS
767	A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products. <i>Current Problems in Cardiology</i> , 2021, , 101011.	1.1	10
768	Forecasting fully vaccinated people against COVID-19 and examining future vaccination rate for herd immunity in the US, Asia, Europe, Africa, South America, and the World. <i>Applied Soft Computing Journal</i> , 2021, 111, 107708.	4.1	47
769	Mucosal IgA response elicited by intranasal immunization of <i>Lactobacillus plantarum</i> expressing surface-displayed RBD protein of SARS-CoV-2. <i>International Journal of Biological Macromolecules</i> , 2021, 190, 409-416.	3.6	21
770	Trends in COVID-19 prevalence and mortality: A year in review. <i>Physica D: Nonlinear Phenomena</i> , 2021, 425, 132968.	1.3	25
771	COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy. <i>European Journal of Cancer</i> , 2021, 157, 441-449.	1.3	43
772	Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103251.	0.9	36
773	A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines. <i>International Immunopharmacology</i> , 2021, 100, 108162.	1.7	65
774	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	0.9	15
775	Shoulder injury related to vaccine administration (SIRVA) following mRNA COVID-19 vaccination: Report of 2 cases of subacromial-subdeltoid bursitis. <i>Radiology Case Reports</i> , 2021, 16, 3631-3634.	0.2	28
776	pDNA and mRNA vaccines. , 2022, , 157-205.		1
779	Preventing Coronavirus Disease 2019 in Kidney Transplant Recipients: Where Should We Begin?. <i>Nephron</i> , 2021, 145, 280-284.	0.9	2
782	The COVID-19 vaccine: A race nearing the finish line. <i>Apollo Medicine</i> , 2021, .	0.0	1
783	Immune Response After One Dose of Intramuscular Vaccination With the BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 Vaccine in Healthcare Workers: The Effect of Age and Vitamin D. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
784	Recombinant chimpanzee adenovirus AdC7 expressing dimeric tandem-repeat spike protein RBD protects mice against COVID-19. <i>Emerging Microbes and Infections</i> , 2021, 10, 1574-1588.	3.0	18
785	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	1.2	18
786	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. , 2021, 12, 155.		25
791	<i>In silico</i> prediction of the <i>in vitro</i> behavior of polymeric gene delivery vectors. <i>Nanoscale</i> , 2021, 13, 8333-8342.	2.8	7
792	Could Vaccine Dose Stretching Reduce COVID-19 Deaths?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
795	Month of Influenza Virus Vaccination Influences Antibody Responses in Children and Adults. <i>Vaccines</i> , 2021, 9, 68.	2.1	4
796	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. <i>Immune Network</i> , 2021, 21, e4.	1.6	26
797	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e2992-e2994.	2.9	11
798	Spatiotemporal Components of Adverse Reactions Against BNT162b2 mRNA SARS-CoV-2 Vaccine Reflect Different Immunological Processes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
799	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. <i>Pediatric Infection and Vaccine</i> , 2021, 28, 7.	0.1	7
800	COVID-19 vaccine failure in a patient on rituximab therapy. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab038.	0.3	10
801	Nanomaterial Delivery Systems for mRNA Vaccines. <i>Vaccines</i> , 2021, 9, 65.	2.1	310
802	A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. <i>AIMS Public Health</i> , 2021, 8, 137-153.	1.1	41
803	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	3.0	202
804	The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	59
805	Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e115.	1.1	111
806	Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience. <i>Journal of Korean Medical Science</i> , 2021, 36, e107.	1.1	57
807	Comparison of Two Highly-Effective mRNA Vaccines for COVID-19 During Periods of Alpha and Delta Variant Prevalence. <i>SSRN Electronic Journal</i> , 0, , .	0.4	34
808	Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?. <i>Science China Life Sciences</i> , 2020, 63, 1833-1849.	2.3	29
809	COVID-19 Vaccines: New Developments and the Road Ahead. <i>Archives of Medical Research</i> , 2020, 52, 454-455.	1.5	2
810	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	2.6	16
811	All eyes on a hurdle race for a SARS-CoV-2 vaccine. <i>Nature</i> , 2020, 586, 501-502.	13.7	23
812	COVID-19 vaccine development: a pediatric perspective. <i>Current Opinion in Pediatrics</i> , 2021, 33, 144-151.	1.0	76

#	ARTICLE	IF	CITATIONS
828	COVID-19 update: the first 6 months of the pandemic. <i>Human Genomics</i> , 2020, 14, 48.	1.4	30
829	COVID-19 vaccines - are we there yet?. <i>Australian Prescriber</i> , 2021, 44, 19-25.	0.5	15
830	The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9775.	1.8	40
831	SARS-CoV-2 Spike Protein and Lung Vascular Cells. <i>Journal of Respiration</i> , 2021, 1, 40-48.	0.4	6
832	Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. <i>Viruses</i> , 2021, 13, 54.	1.5	61
833	Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. <i>Vaccines</i> , 2021, 9, 3.	2.1	74
834	Efficacy and safety of COVID-19 vaccines: a systematic review. <i>Chinese Journal of Contemporary Pediatrics</i> , 2021, 23, 221-228.	0.2	81
835	Neutralizing SARS-CoV-2. <i>ELife</i> , 2020, 9, .	2.8	5
836	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count. <i>SSRN Electronic Journal</i> , 0, , .	0.4	5
837	Appearance of IgG to SARS-CoV-2 in Saliva Effectively Indicates Seroconversion in mRNA Vaccinated Immunocompromised Individuals. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
838	Enfermedad por coronavirus 2019 (COVID-19). <i>Medicina UPB</i> , 2021, 40, 41-49.	0.1	0
839	Eosinophilic granulomatosis with polyangiitis after COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 114, 807-809.	0.2	17
840	Adverse reactions following Pfizer-BioNTech COVID-19 vaccine among Prof. Dr. Alexandru Obregia Clinical Psychiatry Hospital medical staff. <i>Medic Ro</i> , 2021, 4, 9-13.	0.0	0
841	Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination. <i>Viruses</i> , 2021, 13, 1972.	1.5	22
844	Efficacy of Nanoencapsulated Daptomycin in an Experimental Methicillin-Resistant <i>Staphylococcus aureus</i> Bone and Joint Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0076821.	1.4	3
845	Effectiveness of COVID-19 vaccines and their challenges (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1407.	0.8	23
846	Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection. <i>Viruses</i> , 2021, 13, 2003.	1.5	16
847	The Roles of Non-coding RNA in the Development and Regeneration of Hair Follicles: Current Status and Further Perspectives. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 720879.	1.8	12

#	ARTICLE	IF	CITATIONS
848	Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform. <i>Nano Research</i> , 2022, 15, 2196-2225.	5.8	8
850	Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2021, 9, 1145.	2.1	20
851	Long Term Immune Response Produced by the SputnikV Vaccine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11211.	1.8	9
853	Immunogenicity and Safety of the COVID-19 Vaccines Compared With Control in Healthy Adults: A Qualitative and Systematic Review. <i>Value in Health</i> , 2021, , .	0.1	7
854	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
856	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021, 600, 523-529.	13.7	194
857	Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. <i>Vaccines</i> , 2021, 9, 1130.	2.1	36
858	Expression and characterization of SARS-CoV-2 spike proteins. <i>Nature Protocols</i> , 2021, 16, 5339-5356.	5.5	31
860	Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents. <i>Clinical Microbiology and Infection</i> , 2022, 28, 279-284.	2.8	17
861	The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study. <i>Frontiers in Public Health</i> , 2021, 9, 731578.	1.3	11
862	Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy. <i>Vaccines</i> , 2021, 9, 1174.	2.1	13
863	COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. <i>Science Translational Medicine</i> , 2021, 13, eabi8631.	5.8	80
864	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
865	Parents's™ hesitation about getting their children vaccinated against COVID-19 in Japan. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4993-4998.	1.4	30
866	Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 3385.	1.4	3
867	Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. <i>GeroScience</i> , 2021, 43, 2321-2331.	2.1	59
868	Single BNT162b2 vaccine dose produces seroconversion in under 60's cohort. <i>Vaccine</i> , 2021, 39, 6902-6906.	1.7	6
869	Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment. <i>European Journal of Cancer</i> , 2021, 159, 105-112.	1.3	36

#	ARTICLE	IF	CITATIONS
870	Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	21
871	Associations between Allelic Variants of the Human IgH 3 rd Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2021, 9, 1207.	2.1	8
872	Vaccine Refusal in the Czech Republic Is Associated with Being Spiritual but Not Religiously Affiliated. <i>Vaccines</i> , 2021, 9, 1157.	2.1	20
874	Acute Myocarditis after COVID-19 vaccination: A case report. <i>Revue De Medecine Interne</i> , 2021, 42, 797-800.	0.6	21
875	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11
876	COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter?. <i>Vaccines</i> , 2021, 9, 1156.	2.1	39
877	Nanoparticle approaches against SARS-CoV-2 infection. <i>Current Opinion in Solid State and Materials Science</i> , 2021, 25, 100964.	5.6	21
878	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 714170.	2.2	145
879	The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan. <i>PeerJ</i> , 2021, 9, e12316.	0.9	22
880	Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. <i>Immunity and Ageing</i> , 2021, 18, 38.	1.8	20
881	Vaccines against COVID-19: Priority to mRNA-Based Formulations. <i>Cells</i> , 2021, 10, 2716.	1.8	17
882	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
883	Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 3151-3160.	1.4	16
884	Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose. <i>Cureus</i> , 2021, 13, e18880.	0.2	8
885	Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system. <i>Vaccine</i> , 2021, 39, 7066-7073.	1.7	13
886	Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1885-1894.	2.7	13
887	Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer-BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines. <i>Journal of Immunology</i> , 2021, 207, 2405-2410.	0.4	70
888	Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases. <i>Revue Neurologique</i> , 2021, 177, 1262-1265.	0.6	1

#	ARTICLE	IF	CITATIONS
889	Advocating for Greater Inclusion of Marginalized and Forgotten Populations in COVID19 Vaccine Rollouts. <i>International Journal of Public Health</i> , 2021, 66, 1604036.	1.0	13
890	Commercial Interferon-gamma release assay to assess the immune response to first and second doses of mRNA vaccine in previously COVID-19 infected versus uninfected individuals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115573.	0.8	25
891	Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Hematology and Oncology</i> , 2021, 14, 174.	6.9	40
892	Facile Synthesis of N-Doped Graphene Quantum Dots as Novel Transfection Agents for mRNA and pDNA. <i>Nanomaterials</i> , 2021, 11, 2816.	1.9	11
893	Kidney transplant recipientsâ€™ attitudes towards covidâ€™19 vaccination and barriers and enablers to vaccine acceptance. <i>Transplant Infectious Disease</i> , 2021, , e13749.	0.7	12
895	Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	24
896	Presumed Recurrent MEWDS following Covid-19 Vaccination. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1234-1237.	1.0	15
897	Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. <i>International Journal of Pharmaceutics</i> , 2021, 610, 121212.	2.6	11
898	Effectiveness of BNT162b2 mRNA Coronavirus Disease 2019 (COVID-19) Vaccine Against Acquisition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Among Healthcare Workers in Long-Term Care Facilities: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e755-e763.	2.9	18
900	COVID-19 mRNA vaccine allergy. <i>Current Opinion in Pediatrics</i> , 2021, 33, 610-617.	1.0	15
901	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996.	5.8	18
903	A pathogen-like antigen based vaccine confers immune protection against SARS-CoV-2 in non-human primates. <i>Cell Reports Medicine</i> , 2021, 2, 100448.	3.3	11
904	Recent Update of COVID-19 Vaccines. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	0
905	Development of synthetic antigen vaccines for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3855-3870.	1.4	4
906	Immunosuppression reduction when administering a booster dose of the BNT162b2 mRNA SARS-CoV-2 vaccine in kidney transplant recipients without adequate humoral response following two vaccine doses: protocol for a randomised controlled trial (BECAME study). <i>BMJ Open</i> , 2021, 11, e055611.	0.8	22
907	BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. <i>EClinicalMedicine</i> , 2021, 41, 101158.	3.2	64
908	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
909	Comparative safety of mRNA COVIDâ€™19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database. <i>Journal of Medical Virology</i> , 2022, 94, 1085-1095.	2.5	34

#	ARTICLE	IF	CITATIONS
910	Vaccine development and technology for SARS-CoV-2: Current insight. <i>Journal of Medical Virology</i> , 2022, 94, 878-896.	2.5	8
911	COVID-19 vaccine " Long term immune decline and breakthrough infections. <i>Vaccine</i> , 2021, 39, 6984-6989.	1.7	77
912	Epidemiology of COVID-19 in Jiangxi, China. <i>Medicine (United States)</i> , 2021, 100, e27685.	0.4	2
913	Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine. <i>Science Advances</i> , 2021, 7, eabj8065.	4.7	31
914	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. <i>Npj Vaccines</i> , 2021, 6, 128.	2.9	102
915	SARS-CoV-2 Infections Among Patients With Liver Disease and Liver Transplantation Who Received COVID-19 Vaccination. <i>Hepatology Communications</i> , 2022, 6, 889-897.	2.0	36
916	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. <i>Cells</i> , 2021, 10, 2949.	1.8	26
917	Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)"A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 5048.	1.0	9
918	Immunology and controlling of coronaviruses; the current enemy for humanity: A review. <i>International Journal of Biological Macromolecules</i> , 2021, , .	3.6	3
920	Seroconversion rate after vaccination against COVID-19 in patients with cancer"a systematic review. <i>Annals of Oncology</i> , 2022, 33, 158-168.	0.6	59
922	Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. <i>EClinicalMedicine</i> , 2021, 41, 101174.	3.2	57
923	Vaccines and Treatment of Coronavirus Disease 2019. <i>Korean Journal of Medicine</i> , 2020, 95, 364-369.	0.1	1
925	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). <i>Juvenis Scientia</i> , 2020, 6, 41-80.	0.1	0
926	A Digital Health System for Disease Analytics. , 2021, , .		10
927	Science-based COVID-19 vaccine development. <i>National Science Review</i> , 2021, 8, nwab193.	4.6	17
928	Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection). <i>Clinics in Laboratory Medicine</i> , 2022, 42, 111-128.	0.7	8
929	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. <i>Gene Reports</i> , 2021, 25, 101417.	0.4	15
930	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <i>Vaccine</i> , 2021, 39, 7394-7400.	1.7	63

#	ARTICLE	IF	CITATIONS
931	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. <i>Immunity</i> , 2021, 54, 2877-2892.e7.	6.6	260
932	Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2203.	3.8	104
933	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
934	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. <i>Vaccines</i> , 2021, 9, 1261.	2.1	10
935	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. <i>Clinical and Experimental Medicine</i> , 2022, 22, 477-485.	1.9	18
936	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
937	A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache. <i>Panminerva Medica</i> , 2021, 63, 324-331.	0.2	8
938	Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05035.	0.2	2
940	Antibody responses to the SARS-CoV-2 vaccines in hemodialysis patients: Is inactivated vaccine effective?. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 769-774.	0.4	8
941	Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age. <i>Vaccines</i> , 2021, 9, 1277.	2.1	1
943	Authorization of the first COVID-19 emergency vaccines: The matters arising. <i>EXCLI Journal</i> , 2021, 20, 655-660.	0.5	2
944	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, Ribonuclease I and Human RNase A. <i>Frontiers in Microbiology</i> , 2021, 12, 660149.	1.5	1
945	Efficacy and safety of potential vaccine candidates against coronavirus disease 2019: A systematic review. <i>Journal of Advanced Pharmaceutical Technology and Research</i> , 2021, 12, 215-221.	0.4	2
946	Cardiovascular injuries and SARS-COV-2 infection: focus on elderly people. <i>Journal of Geriatric Cardiology</i> , 2021, 18, 534-548.	0.2	2
947	Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes. <i>Clinical Infectious Diseases</i> , 2022, 75, e695-e704.	2.9	23
948	The Non-coding MicroRNA-223 is a Promising Biomarker of Chronic Kidney Disease. , 0, , 91-95.		0
949	RNA-based vaccines against SARS-CoV-2. , 2022, , 129-152.		1
950	Humoral Immunogenicity of mRNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease and Healthy Controls. <i>American Journal of Gastroenterology</i> , 2022, 117, 176-179.	0.2	36

#	ARTICLE	IF	CITATIONS
952	Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103415.	0.9	6
954	Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. <i>American Journal of Hematology</i> , 2022, 97, E27.	2.0	5
955	COVID-19 vaccinations: The unknowns, challenges, and hopes. <i>Journal of Medical Virology</i> , 2022, 94, 1336-1349.	2.5	75
956	Vaccines and Vaccination Strategies for Older Adults. <i>Healthy Ageing and Longevity</i> , 2022, , 119-164.	0.2	1
957	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22
958	Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in <i>Nicotiana benthamiana</i> Plant as a Vaccine Candidate against COVID-19. <i>Vaccines</i> , 2021, 9, 1337.	2.1	28
959	SARS-CoV-2: Overview and Its Impact on Oral Health. <i>Biomedicines</i> , 2021, 9, 1690.	1.4	7
960	Power in Numbers: Harnessing Combinatorial and Integrated Screens to Advance Nanomedicine. <i>Jacs Au</i> , 2022, 2, 12-21.	3.6	10
961	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. <i>IScience</i> , 2021, , 103379.	1.9	8
962	Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. <i>Frontiers in Immunology</i> , 2021, 12, 778679.	2.2	54
963	Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 416-421.	0.5	19
964	Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 752233.	2.2	68
965	Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. <i>Frontiers in Immunology</i> , 2021, 12, 779212.	2.2	35
966	The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data. <i>Vaccines</i> , 2021, 9, 1328.	2.1	9
967	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. <i>Journal of Infectious Diseases</i> , 2022, 225, 777-784.	1.9	21
968	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
969	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. <i>Vaccines</i> , 2021, 9, 1409.	2.1	22
970	Developmental Aspects of SARS-CoV-2, Potential Role of Exosomes and Their Impact on the Human Transcriptome. <i>Journal of Developmental Biology</i> , 2021, 9, 54.	0.9	5

#	ARTICLE	IF	CITATIONS
971	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0012321.	5.7	10
972	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. <i>Vaccines</i> , 2021, 9, 1338.	2.1	17
973	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
974	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. <i>Journal of Virology</i> , 2022, 96, JVI0155121.	1.5	18
975	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
976	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Pathogens</i> , 2021, 10, 1537.	1.2	19
977	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
978	Multicolor Flow Cytometry and High-Dimensional Data Analysis to Probe Complex Questions in Vaccinology. <i>Methods in Molecular Biology</i> , 2022, 2414, 433-447.	0.4	1
979	Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans. <i>Immuno</i> , 2021, 1, 442-456.	0.6	7
981	COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation. <i>PLoS ONE</i> , 2021, 16, e0244415.	1.1	63
982	The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials. <i>Cancers</i> , 2021, 13, 5924.	1.7	19
983	Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies. <i>Diagnostics</i> , 2021, 11, 2193.	1.3	4
984	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120
985	Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. <i>International Immunopharmacology</i> , 2021, 101, 108351.	1.7	36
986	Comparison of the immunogenicity of <scp>BNT162b2</scp> and <scp>CoronaVac COVID</scp>â€19 vaccines in Hong Kong. <i>Respirology</i> , 2022, 27, 301-310.	1.3	127
987	Possibility of exosomeâ€based coronavirus disease 2019 vaccine (Review). <i>Molecular Medicine Reports</i> , 2021, 25, .	1.1	18
988	COVIDâ€19 vaccination timing and kidney transplant waitlist management: An international perspective. <i>Transplant Infectious Disease</i> , 2022, 24, e13763.	0.7	8
990	Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 5498.	1.0	12

#	ARTICLE	IF	CITATIONS
991	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. <i>New England Journal of Medicine</i> , 2022, 386, 35-46.	13.9	431
992	Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114041.	6.6	26
993	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57
994	High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. <i>Microbiology Spectrum</i> , 2021, 9, e0096521.	1.2	17
999	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4714-4740.	1.4	16
1000	The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. <i>IScience</i> , 2021, 24, 103479.	1.9	224
1001	Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. <i>Microbiology Spectrum</i> , 2021, 9, e0056121.	1.2	15
1002	SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. <i>IScience</i> , 2021, 24, 103467.	1.9	26
1003	Temporal variations in country-specific mutational profiles of SARS-CoV-2: effect on vaccine efficacy. <i>Future Virology</i> , 2021, 16, 805-819.	0.9	2
1004	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0
1005	Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older. <i>Journal of Korean Medical Science</i> , 2021, 36, e318.	1.1	12
1006	Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. <i>Journal of Korean Medical Science</i> , 2021, 36, e311.	1.1	33
1007	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
1008	Higher Antibody Concentrations in Health Care Workers Associated With Greater Reactogenicity Post-Vaccination. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1009	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. <i>Nanoscale</i> , 2022, 14, 1054-1074.	2.8	22
1010	Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G. <i>Internal Medicine</i> , 2022, 61, 811-819.	0.3	6
1011	Determinants of Immune Response to Anti-“SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study. <i>Transplantation</i> , 2022, 106, 842-852.	0.5	21
1012	Genome sequencing of SARS-CoV-2 reveals the prevalence of variant B.1.1.7 in Egypt. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105191.	1.0	3

#	ARTICLE	IF	CITATIONS
1013	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 445-454.	1.3	5
1014	Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination. <i>Bone Marrow Transplantation</i> , 2022, 57, 502-503.	1.3	9
1016	Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges. <i>Journal of Controlled Release</i> , 2022, 342, 345-361.	4.8	82
1017	Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103455.	0.9	13
1018	ACE2 Overexpressing Mesenchymal Stem Cells Alleviates COVID-19 Lung Injury by Inhibiting Pyroptosis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1019	Predictive Analytics to Support Health Informatics on COVID-19 Data. , 2021, , .		6
1020	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. <i>Cell and Bioscience</i> , 2021, 11, 202.	2.1	13
1021	Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants. <i>Clinical and Translational Medicine</i> , 2021, 11, e644.	1.7	7
1022	COVID-19 vaccines: challenges and solutions. <i>Minerva Respiratory Medicine</i> , 2022, 60, .	0.1	1
1023	Potential Application of Bionanoparticles to Treat Severe Acute Respiratory Syndrome Coronavirus-2 Infection. <i>Frontiers in Nanotechnology</i> , 2022, 3, .	2.4	5
1024	Extended interval BNT162b2 vaccination enhances peak antibody generation. <i>Npj Vaccines</i> , 2022, 7, 14.	2.9	101
1025	The BNT162b2 mRNA Covid-19 vaccine does not impair sperm parameters. <i>Reproductive BioMedicine Online</i> , 2022, 44, 685-688.	1.1	43
1026	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. <i>Med</i> , 2022, 3, 28-41.e8.	2.2	19
1028	Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. <i>Cell</i> , 2022, 185, 1025-1040.e14.	13.5	243
1030	Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses. <i>PLoS Pathogens</i> , 2022, 18, e1010255.	2.1	15
1031	Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers. <i>Public Health</i> , 2022, 205, 1-5.	1.4	2
1032	Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 32.	2.3	7
1033	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. <i>Lancet Microbe</i> , The, 2022, 3, e193-e202.	3.4	45

#	ARTICLE	IF	CITATIONS
1035	Metainflammation in COVID-19. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1154-1166.	0.6	7
1036	SARS-CoV-2 BNT162b2 vaccine-induced humoral response and reactogenicity in individuals with prior COVID-19 disease. <i>JCI Insight</i> , 2022, 7, .	2.3	5
1037	A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection. <i>Science Advances</i> , 2022, 8, eabh3827.	4.7	27
1038	Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 75.	2.1	8
1040	Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. <i>Microbiology Spectrum</i> , 2022, 10, e0118121.	1.2	15
1041	Induction of humoral and cellular immune responses to COVID-19 mRNA and vector vaccines: A prospective cohort study in Bulgarian healthcare workers. <i>Journal of Medical Virology</i> , 2022, 94, 2008-2018.	2.5	11
1042	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
1043	Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination. <i>Vaccines</i> , 2022, 10, 154.	2.1	8
1044	Discovery of compounds inhibiting SARS-COV-2 multi-targets. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 2602-2617.	2.0	3
1045	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. <i>Cell Reports</i> , 2022, 38, 110235.	2.9	35
1046	Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa. <i>Nanomaterials</i> , 2022, 12, 226.	1.9	20
1047	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. <i>EBioMedicine</i> , 2022, 75, 103762.	2.7	32
1048	Polymorphism of the <sc>HLA</sc> system and weak antibody response to <sc>BNT162b2 mRNA</sc> vaccine. <i>Hla</i> , 2022, 99, 183-191.	0.4	15
1049	Initial comparative analysis of pulmonary involvement on HRCT between vaccinated and non-vaccinated subjects of COVID-19. <i>European Radiology</i> , 2022, 32, 4275-4283.	2.3	17
1050	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	2.1	13
1051	Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection. <i>Cancer Control</i> , 2022, 29, 107327482110707.	0.7	3
1052	Population homogeneity for the antibody response to COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age ranges. <i>Nature Communications</i> , 2022, 13, 140.	5.8	22
1053	COVID-specific T's may offset therapeutically endangered B's. <i>Blood</i> , 2022, 139, 12-13.	0.6	1

#	ARTICLE	IF	CITATIONS
1054	Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. <i>Journal of Clinical Medicine</i> , 2022, 11, 694.	1.0	10
1055	Changes in sexual behaviour, anxiety symptoms, and quality of couple relationship of patients with infertility during the COVID-19 lockdown. <i>Journal of Assisted Reproduction and Genetics</i> , 2022, 39, 493-504.	1.2	5
1056	Recurrence of Varicella-Zoster Virus Keratitis After SARS-CoV-2 Vaccination. <i>Cornea</i> , 2022, 41, 649-650.	0.9	5
1057	Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study. <i>Vaccine</i> , 2022, 40, 437-443.	1.7	5
1058	SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021. <i>Frontiers in Microbiology</i> , 2021, 12, 796807.	1.5	5
1059	Estimating a continuously varying offset between multivariate time series with application to COVID-19 in the United States. <i>European Physical Journal: Special Topics</i> , 2022, 231, 3419-3426.	1.2	17
1060	Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. <i>Vaccine</i> , 2022, 40, 650-655.	1.7	17
1061	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. <i>Vaccines</i> , 2022, 10, 160.	2.1	33
1062	Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study. <i>EBioMedicine</i> , 2022, 75, 103810.	2.7	17
1063	Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. <i>Blood</i> , 2022, 139, 1409-1412.	0.6	28
1064	Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. <i>Journal of Disaster Research</i> , 2022, 17, 7-20.	0.4	2
1065	COVID-19 Vaccination in Cancer Patients Older Than 70 Years Undergoing Active Treatment. Seroconversion Rate and Safety. <i>Vaccines</i> , 2022, 10, 164.	2.1	7
1066	Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID-19 vaccine. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 961-974.	1.9	12
1067	Assessment of COVID-19 mRNA vaccination titer and side effects in healthy volunteers. <i>Laboratoriums Medizin</i> , 2022, 46, 107-114.	0.1	6
1068	Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. <i>JCI Insight</i> , 2022, 7, .	2.3	69
1069	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. <i>Med</i> , 2022, 3, 137-153.e3.	2.2	19
1070	mRNA Vaccines in the COVID-19 Pandemic and Beyond. <i>Annual Review of Medicine</i> , 2022, 73, 17-39.	5.0	120
1071	New-onset Polymyalgia Rheumatica Following the Administration of the Pfizer-BioNTech COVID-19 Vaccine. <i>Internal Medicine</i> , 2022, 61, .	0.3	12

#	ARTICLE	IF	CITATIONS
1074	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet</i> , The, 2022, 399, 36-49.	6.3	161
1075	Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine. <i>Life</i> , 2022, 12, 57.	1.1	6
1076	Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2022, 5, e2143955.	2.8	99
1077	Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4747-4754.	1.4	6
1078	Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell) Inactivated in Patients Over 60 Years of Age With Hypertension and Diabetes Mellitus. <i>SSRN Electronic Journal</i> , 0, .	0.4	0
1079	Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size. <i>Pharmaceutical Research</i> , 2022, 39, 105-114.	1.7	48
1080	Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e495-e497.	0.2	2
1081	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0239021.	1.8	5
1082	Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. <i>PLoS ONE</i> , 2022, 17, e0260733.	1.1	60
1083	COVID-19 mRNA Vaccination Mimicking Heart Attack in a Healthy 56-Year-Old Physician. <i>Infectious Disease Reports</i> , 2022, 14, 93-97.	1.5	1
1084	Fluorescence Correlation Spectroscopy Monitors the Fate of Degradable Nanocarriers in the Blood Stream. <i>Biomacromolecules</i> , 2022, 23, 1065-1074.	2.6	15
1085	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. <i>New England Journal of Medicine</i> , 2022, 386, 951-963.	13.9	102
1086	Optimal Timing of COVID-19 Vaccination in the Peri-Transplant Period: A Single Institution Case Series. <i>Transplantation Proceedings</i> , 2022, 54, 1409-1411.	0.3	1
1087	Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. <i>Cell</i> , 2022, 185, 1008-1024.e15.	13.5	101
1088	SARS COV-2 anti-nucleocapsid and anti-spike antibodies in an emergency department healthcare worker cohort: September 2020 – April 2021. <i>American Journal of Emergency Medicine</i> , 2022, 54, 81-86.	0.7	3
1089	Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e878-e879.	2.9	20
1090	OS DESAFIOS DA SAÚDE DIGITAL NA PANDEMIA DE COVID-19: UMA REVISÃO INTEGRATIVA NO SCIELO. <i>Recisatec</i> , 2022, 2, e2182.	0.0	0
1091	Young age, female sex, and presence of systemic adverse reactions are associated with high post-vaccination antibody titer after two doses of BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese healthcare workers and university staff. <i>Vaccine</i> , 2022, 40, 1019-1025.	1.7	43

#	ARTICLE	IF	CITATIONS
1092	Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers: Changing Epidemiology as the Pandemic Progresses. <i>Frontiers in Medicine</i> , 2021, 8, 758118.	1.2	15
1093	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
1094	Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection—A comparative study from Novi Sad, Serbia. <i>PLoS ONE</i> , 2022, 17, e0263468.	1.1	33
1095	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
1096	Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2022, 116, 47-50.	1.5	10
1097	Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112650.	2.5	30
1098	Comparing the dynamics of COVID-19 infection and mortality in the United States, India, and Brazil. <i>Physica D: Nonlinear Phenomena</i> , 2022, 432, 133158.	1.3	23
1099	COVID-19 vaccine therapeutic trials review: published results and registered protocols. <i>Journal of Global Health Reports</i> , 0, 5, .	1.0	0
1100	Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring. <i>Vaccine</i> , 2022, 40, 1390-1396.	1.7	11
1101	Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1853.	1.2	9
1102	Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2381-2392.	2.7	14
1103	Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2. <i>PLoS ONE</i> , 2022, 17, e0262922.	1.1	10
1104	An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity. <i>Cell</i> , 2022, 185, 614-629.e21.	13.5	40
1105	Immune titers of protection against severe acute respiratory syndrome coronavirus 2: are we there yet?. <i>Exploration of Immunology</i> , 0, , 9-24.	1.7	5
1106	Comparison of the Anti-SARS-CoV-2 Surrogate Neutralization Assays by TECOmedical and DiaPROPH-Med with Samples from Vaccinated and Infected Individuals. <i>Viruses</i> , 2022, 14, 315.	1.5	8
1107	Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2. <i>Frontiers in Medicine</i> , 2022, 9, 811004.	1.2	3
1108	Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals. <i>Viruses</i> , 2022, 14, 370.	1.5	5
1109	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12

#	ARTICLE	IF	CITATIONS
1110	Factors Affecting Young Adults's™ Decision Making to Undergo COVID-19 Vaccination: A Patient Preference Study. <i>Vaccines</i> , 2022, 10, 265.	2.1	2
1111	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
1113	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
1114	Are There Hidden Genes in DNA/RNA Vaccines?. <i>Frontiers in Immunology</i> , 2022, 13, 801915.	2.2	9
1115	BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort. <i>Gerontology</i> , 2022, 68, 1350-1357.	1.4	9
1116	Vaccination and COVID-19 Dynamics in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 395-402.	2.2	33
1118	Efficacy of antibody response following the vaccination of SARS-CoV-2 infected and noninfected healthcare workers by two-dose inactivated vaccine against COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 2431-2437.	2.5	4
1119	Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 6574-6585.	2.5	9
1120	Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. <i>JAMA Internal Medicine</i> , 2022, 182, 153.	2.6	182
1121	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	65
1122	CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, , 1-10.	1.4	0
1123	The Impact of B-cell Directed Therapy on SARS-CoV-2 Vaccine Efficacy in CLL. <i>British Journal of Haematology</i> , 2022, , .	1.2	11
1124	Factors affecting intention to take COVID-19 vaccine among Pakistani University Students. <i>PLoS ONE</i> , 2022, 17, e0262305.	1.1	8
1125	Analytical characterization of the SARS-CoV-2 EURM-017 reference material. <i>Clinical Biochemistry</i> , 2022, 101, 19-25.	0.8	5
1126	Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine. <i>Transplantation Direct</i> , 2022, 8, e1257.	0.8	10
1127	Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. <i>Nature Communications</i> , 2021, 12, 7101.	5.8	100
1128	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. <i>Nature Communications</i> , 2021, 12, 7217.	5.8	80
1129	Deep dissection of the antiviral immune profile of patients with COVID-19. <i>Communications Biology</i> , 2021, 4, 1389.	2.0	9

#	ARTICLE	IF	CITATIONS
1130	Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. <i>Journal of Infectious Diseases</i> , 2022, 225, 1701-1709.	1.9	9
1131	Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19 Convalescent Individuals. <i>Journal of Infectious Diseases</i> , 2022, 225, 1905-1908.	1.9	14
1136	Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial. <i>Infectious Diseases of Poverty</i> , 2021, 10, 138.	1.5	16
1137	Comparison of the Development of SARS-Coronavirus-2-Specific Cellular Immunity, and Central Memory CD4+ T-Cell Responses Following Infection versus Vaccination. <i>Vaccines</i> , 2021, 9, 1439.	2.1	8
1139	Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals. <i>Science Translational Medicine</i> , 2021, , eabi8961.	5.8	22
1141	Pre-Clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1142	Antibody response of smokers to the COVID-19 vaccination: Evaluation based on cigarette dependence. <i>Drug Discoveries and Therapeutics</i> , 2022, 16, 78-84.	0.6	5
1143	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1144	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
1145	Clinicopathological Characteristics of Inflammatory Myositis Induced by COVID-19 Vaccine (Pfizer-BioNTech BNT162b2): A Case Report. <i>Journal of Korean Medical Science</i> , 2022, 37, e91.	1.1	16
1146	A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192210892.	1.0	21
1147	Clinical recrudescence of chronic untreated P. malariae infection after BNT162b2 CoVID-19 vaccine. <i>IDCases</i> , 2022, 27, e01456.	0.4	2
1149	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	3.5	105
1150	Immune Response of Adult Sickle Cell Disease Patients after COVID-19 Vaccination: The Experience of a Greek Center. <i>Journal of Clinical Medicine</i> , 2022, 11, 937.	1.0	7
1152	Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. <i>Vaccines</i> , 2022, 10, 290.	2.1	18
1153	mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. <i>Life Science Alliance</i> , 2022, 5, e202201381.	1.3	29
1154	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
1155	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	7.7	10

#	ARTICLE	IF	CITATIONS
1156	The Humoral Immune Response of the ChAdOx1 nCoV-19 Vaccine in Maintenance Dialysis Patients without Prior COVID-19 Infection. <i>Vaccines</i> , 2022, 10, 338.	2.1	5
1157	Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1115-1126.	1.0	63
1158	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 485-488.e3.	5.1	80
1159	Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of Antibody Titers. <i>Vaccines</i> , 2022, 10, 377.	2.1	30
1160	The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study. <i>Microbiology Spectrum</i> , 2022, 10, e0140221.	1.2	20
1161	Smart Vaccine Manufacturing Using Novel Biotechnology Platforms: A Study During COVID-19. <i>Journal of Computing and Information Science in Engineering</i> , 2022, 22, .	1.7	2
1162	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. <i>Npj Vaccines</i> , 2022, 7, 28.	2.9	64
1163	Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. <i>Immunologic Research</i> , 2022, 70, 289-315.	1.3	34
1164	Severity of Covid-19 infection among kidney transplant recipients in Duhok city, Kurdistan region, Iraq. <i>Journal of Contemporary Medical Sciences</i> , 2022, 8, .	0.1	0
1165	Ofelecin i mi Vlapinâ€™ Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309.	0.8	4
1166	Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics. <i>Pharmaceutics</i> , 2022, 14, 398.	2.0	31
1167	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	2.1	5
1168	COVID-19 mRNA vaccines: Platforms and current developments. <i>Molecular Therapy</i> , 2022, 30, 1850-1868.	3.7	102
1169	Assessing the reporting quality of randomized controlled trials on COVID-19 vaccines: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	1
1170	Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 677-685.	1.2	7
1171	Lack of association between pandemic chilblains and SARS-CoV-2 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	18
1172	Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 675-684.	2.0	24
1173	Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCoV-19 vaccine. <i>Clinical Microbiology and Infection</i> , 2022, , .	2.8	1

#	ARTICLE	IF	CITATIONS
1174	Nonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy. <i>Pharmaceutics</i> , 2022, 14, 512.	2.0	19
1175	Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination. <i>JAMA Oncology</i> , 2022, 8, 201.	3.4	17
1176	Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. <i>Leukemia</i> , 2022, 36, 1176-1179.	3.3	3
1178	SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. <i>Cell</i> , 2022, 185, 603-613.e15.	13.5	176
1179	Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. <i>Nature Computational Science</i> , 2022, 2, 123-131.	3.8	39
1181	Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021. <i>Viruses</i> , 2022, 14, 568.	1.5	17
1183	Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2022, 197, 576-579.	1.2	6
1184	Case Report: Two Case Reports of Acute Myopericarditis After mRNA COVID-19 Vaccine. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 827237.	1.1	6
1185	Immunogenic Epitope-Based Vaccine Prediction from Surface Glycoprotein of MERS-CoV by Deploying Immunoinformatics Approach. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 77.	0.9	5
1187	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
1188	Current Status and Future Perspectives on mRNA Drug Manufacturing. <i>Molecular Pharmaceutics</i> , 2022, 19, 1047-1058.	2.3	44
1189	The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 934-940.	1.4	5
1190	Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. <i>Clinical Immunology</i> , 2022, 236, 108961.	1.4	9
1191	A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. <i>Dermatologic Therapy</i> , 2022, 35, e15461.	0.8	31
1192	mRNA Lipoplexes with Cationic and Ionizable β -Amino-lipophosphonates: Membrane Fusion, Transfection, mRNA Translation and Conformation. <i>Pharmaceutics</i> , 2022, 14, 581.	2.0	3
1193	Rational Development of a Polysaccharide-Protein-Conjugated Nanoparticle Vaccine Against SARS-CoV-2 Variants and <i>Streptococcus pneumoniae</i> . <i>Advanced Materials</i> , 2022, 34, e2200443.	11.1	11
1194	Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	27
1195	Coronavirus Disease-2019 in Older People with Cognitive Impairment. <i>Clinics in Geriatric Medicine</i> , 2022, 38, 501-517.	1.0	3

#	ARTICLE	IF	CITATIONS
1197	Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy. <i>Molecules</i> , 2022, 27, 1943.	1.7	22
1198	Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines. <i>Journal of Microbiology</i> , 2022, 60, 308-320.	1.3	6
1199	Evaluation of Adverse Effects in Nursing Mothers and Their Infants After COVID-19 mRNA Vaccination. <i>Breastfeeding Medicine</i> , 2022, 17, 412-421.	0.8	3
1200	Pledging to Address Scientific Bias in Published Literature. <i>Clinical Therapeutics</i> , 2022, , .	1.1	3
1201	Adverse Events Following BNT162b2 mRNA COVID-19 Vaccine Immunization among Healthcare Workers in a Tertiary Hospital in Johor, Malaysia. <i>Vaccines</i> , 2022, 10, 509.	2.1	5
1202	Addressing the Elephant in the Room: Intravenous Injection of COVID-19 mRNA. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	1
1204	Probable treatment options for Covid-19: A brief review. <i>IP International Journal of Comprehensive and Advanced Pharmacology</i> , 2022, 7, 17-26.	0.1	0
1205	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
1206	Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study. <i>Vaccines</i> , 2022, 10, 417.	2.1	4
1207	Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects. <i>European Journal of Immunology</i> , 2022, 52, 816-824.	1.6	31
1208	Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103737.	0.9	13
1209	Safety and Efficacy of the Common Vaccines against COVID-19. <i>Vaccines</i> , 2022, 10, 513.	2.1	27
1210	Current Developments and Challenges of mRNA Vaccines. <i>Annual Review of Biomedical Engineering</i> , 2022, 24, 85-109.	5.7	39
1211	Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. <i>Nature Immunology</i> , 2022, 23, 543-555.	7.0	185
1212	Elevated CD21 ^{low} B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 716-727.	2.0	13
1214	miRNAs in SARS-CoV-2 Infection: An Update. <i>Current Drug Metabolism</i> , 2022, 23, .	0.7	2
1215	Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients. <i>Frontiers in Microbiology</i> , 2022, 13, 816778.	1.5	12
1216	Genetic alteration of human MYH6 is mimicked by SARS-CoV-2 polyprotein: mapping viral variants of cardiac interest. <i>Cell Death Discovery</i> , 2022, 8, 124.	2.0	4

#	ARTICLE	IF	CITATIONS
1218	The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists. <i>Thrombosis and Haemostasis</i> , 2022, 122, 377-385.	1.8	5
1219	Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals. <i>MBio</i> , 2022, 13, e0379821.	1.8	28
1220	Postvaccination SARS-CoV-2 Infections among Healthcare Professionals: A Real World Evidence Study. <i>Vaccines</i> , 2022, 10, 511.	2.1	1
1221	Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience. <i>Medicina (Lithuania)</i> , 2022, 58, 441.	0.8	3
1222	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. <i>AAPS PharmSciTech</i> , 2022, 23, 95.	1.5	3
1224	COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3111.	1.2	1
1225	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. <i>RNA Biology</i> , 2022, 19, 386-410.	1.5	19
1226	Cellular and humoral responses to SARS-CoV-2 vaccination in immunosuppressed patients. <i>Cellular Immunology</i> , 2022, 373, 104501.	1.4	3
1227	Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review. <i>Cureus</i> , 2022, 14, e23526.	0.2	31
1228	ChAdOx1 nCoV-19 Vaccine Side Effects among Healthcare Workers in Trinidad and Tobago. <i>Vaccines</i> , 2022, 10, 466.	2.1	6
1229	SARS-CoV-2 infection and children: Insights from the 6th Workshop on Paediatric Virology (Review). <i>World Academy of Sciences Journal</i> , 2022, 4, .	0.4	1
1230	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	5.8	48
1231	Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. <i>Vaccine</i> , 2022, 40, 1924-1927.	1.7	20
1232	Time-Dependent Changes in Death Reports and the Sex Ratio in the Safety Surveillance of SARS-CoV-2 Vaccination in Japan, the United States, and European Countries. <i>Cureus</i> , 2022, 14, e23380.	0.2	2
1233	Nanotechnology and COVID-19: quo vadis?. <i>Journal of Nanoparticle Research</i> , 2022, 24, 62.	0.8	6
1234	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. <i>Npj Vaccines</i> , 2022, 7, 31.	2.9	21
1236	Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury. <i>Digestive and Liver Disease</i> , 2022, 54, 722-726.	0.4	8
1238	Pandemic-response adenoviral vector and RNA vaccine manufacturing. <i>Npj Vaccines</i> , 2022, 7, 29.	2.9	12

#	ARTICLE	IF	CITATIONS
1239	A COVID-19 Primer for Primary Care Clinicians. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2022, , 101180.	0.8	2
1240	SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 448.	2.1	24
1241	The Fundamental Flaws of the CNBSS Trials: A Scientific Review. <i>Journal of Breast Imaging</i> , 2022, 4, 108-119.	0.5	11
1242	Adverse events following vaccination against coronavirus disease 2019. <i>Kosin Medical Journal</i> , 2022, 37, 18-26.	0.1	0
1243	Caring for older adults during the COVID-19 pandemic. <i>Clinical Microbiology and Infection</i> , 2022, 28, 785-791.	2.8	21
1244	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386.	1.1	5
1245	Factors associated with the intention to participate in COVID-19 vaccine clinical trials: A cross-sectional study in Peru. <i>Vaccine</i> , 2022, , .	1.7	0
1246	mRNA- and Adenovirus-Based Vaccines against SARS-CoV-2 in HIV-Positive People. <i>Viruses</i> , 2022, 14, 748.	1.5	11
1247	Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis. <i>Biomedicines</i> , 2022, 10, 834.	1.4	16
1248	Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, S1175-S1179.	0.9	11
1249	ACE2 overexpressing mesenchymal stem cells alleviates COVID-19 lung injury by inhibiting pyroptosis. <i>IScience</i> , 2022, 25, 104046.	1.9	4
1250	Whatâ€™s Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics. <i>Bioconjugate Chemistry</i> , 2022, 33, 1996-2007.	1.8	7
1251	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. <i>EBioMedicine</i> , 2022, 78, 103962.	2.7	8
1252	Effectiveness, Adverse Events, and Immune Response Following Double Vaccination with BNT162b2 in Staff at the National Comprehensive Cancer Center (NCCC). <i>Vaccines</i> , 2022, 10, 558.	2.1	2
1253	Outcomes of single dose COVID-19 vaccines: Eight month follow-up of a large cohort in Saudi Arabia. <i>Journal of Infection and Public Health</i> , 2022, 15, 573-577.	1.9	7
1254	Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults. <i>BMJ Open</i> , 2022, 12, e056872.	0.8	12
1255	Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine. <i>Vaccine</i> , 2022, 40, 2993-2998.	1.7	1
1256	Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine. <i>Clinical Immunology</i> , 2022, 237, 108963.	1.4	4

#	ARTICLE	IF	CITATIONS
1257	The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN- γ release by natural killer cells. <i>Vaccine</i> , 2022, 40, 2619-2625.	1.7	6
1258	Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals. <i>EBioMedicine</i> , 2022, 78, 103972.	2.7	31
1259	Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study. <i>Canadian Journal of Public Health</i> , 2022, 113, 385-393.	1.1	3
1260	Influence of social media on the public perspectives of the safety of COVID-19 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1697-1699.	2.0	7
1262	Maximizing COVID-19 Vaccine Acceptance in Developing Countries. , 0, , .		0
1263	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
1264	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 “a review. <i>Translational Research</i> , 2022, 242, 1-19.	2.2	3
1265	Plant-based expression and characterization of SARS-CoV-2 virus-like particles presenting a native spike protein. <i>Plant Biotechnology Journal</i> , 2022, 20, 1363-1372.	4.1	23
1266	BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?. <i>EMBO Molecular Medicine</i> , 2022, 14, e15326.	3.3	30
1267	Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. <i>Frontiers in Immunology</i> , 2022, 13, 882856.	2.2	4
1268	Acute disseminated encephalomyelitis (ADEM) after SARS- CoV-2 vaccination: A case report. <i>Radiology Case Reports</i> , 2022, 17, 1789-1793.	0.2	16
1269	mRNA vaccines for COVID-19 and diverse diseases. <i>Journal of Controlled Release</i> , 2022, 345, 314-333.	4.8	50
1270	Trajectory of SARS-CoV-2 anti-S IgG levels following transfusion and a third dose of BNT162b2 vaccine in a patient with massive postoperative bleeding: A case report. <i>International Journal of Infectious Diseases</i> , 2022, 118, 138-140.	1.5	0
1271	Stroke Associated with COVID-19 Vaccines. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106440.	0.7	21
1272	Age and vitamin D affect the magnitude of the antibody response to the first dose of the SARS-CoV-2 BNT162b2 vaccine. <i>Current Research in Translational Medicine</i> , 2022, 70, 103344.	1.2	22
1273	Pharmacokinetics of convalescent plasma therapy in a COVID-19 patient with X-linked Agammaglobulinemia. <i>Clinical Immunology Communications</i> , 2022, 2, 57-61.	0.5	2
1274	Effectiveness and Safety of COVID-19 Vaccine. <i>Trends in the Sciences</i> , 2021, 26, 10_18-10_25.	0.0	0
1275	mRNAç—æ³•çš„ç”ç©¶è¿Ÿâ±•ăžæE’æ~. <i>Scientia Sinica Vitae</i> , 2023, 53, 30-49.	0.1	1

#	ARTICLE	IF	CITATIONS
1276	Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Molecular Biology</i> , 2021, 55, 889-898.	0.4	12
1277	Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab575.	0.4	43
1278	Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 435.	7.1	11
1279	CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. <i>BMJ Open</i> , 2021, 11, e054208.	0.8	7
1280	The Impact of Age Difference on the Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 758294.	2.2	43
1281	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. <i>World Journal of Hepatology</i> , 2021, 13, 1850-1874.	0.8	10
1282	Effects of Influenza Vaccination on the Response to BNT162b2 Messenger RNA COVID-19 Vaccine in Healthcare Workers. <i>Journal of Clinical Medicine Research</i> , 2021, 13, 549-555.	0.6	8
1284	SARS-CoV-2 Infection During Pregnancy and Associated Perinatal Health Outcomes: A National US Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 759-767.	1.9	32
1285	Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 759688.	2.2	29
1286	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435.	2.1	8
1288	Herpes simplex virus interference with immunity: Focus on dendritic cells. <i>Virulence</i> , 2021, 12, 2583-2607.	1.8	7
1289	Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization. <i>Viruses</i> , 2021, 13, 2440.	1.5	8
1290	Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls. <i>Transplant Infectious Disease</i> , 2022, 24, e13772.	0.7	21
1292	Vaccine-induced immune responses against SARS-CoV-2 infections. <i>Exploration of Immunology</i> , 0, , 356-373.	1.7	0
1293	<i>De novo</i> and relapsing necrotizing vasculitis after COVID-19 vaccination. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 560-563.	1.4	21
1294	Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma. <i>BMC Cancer</i> , 2021, 21, 1354.	1.1	9
1295	Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 791660.	1.8	32
1296	The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5271-5285.	1.1	16

#	ARTICLE	IF	CITATIONS
1297	Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK. <i>Vaccines</i> , 2021, 9, 1460.	2.1	8
1299	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. <i>Nature Communications</i> , 2021, 12, 7105.	5.8	22
1300	mRNA Vaccines to Protect Against Diseases. <i>Methods in Molecular Biology</i> , 2022, 2410, 111-129.	0.4	2
1302	Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 8141-8158.	3.3	12
1304	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
1306	Nanoscience versus Viruses: The SARS-CoV-2 Case. <i>Advanced Functional Materials</i> , 2022, 32, 2107826.	7.8	8
1307	Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. <i>Frontiers in Immunology</i> , 2021, 12, 793191.	2.2	16
1309	Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1516-1524.e2.	2.4	57
1311	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 978-985.	0.9	17
1312	The cold chain for the conservation of vaccines against covid-19: systemic review. <i>Pro Sciences</i> , 2021, 5, 282-289.	0.0	0
1313	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. <i>Cell Transplantation</i> , 2022, 31, 096368972210902.	1.2	3
1315	Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2.HLA-DR4.Rag1KO.IL-2R ³ cKO.NOD) for COVID-19. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-16.	1.4	6
1316	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
1318	Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS). <i>Clinical Infectious Diseases</i> , 2022, 75, 1971-1979.	2.9	12
1319	Advanced Functions Embedded in the Second Version of Database, Global Evaluation of SARS-CoV-2/hCoV-19 Sequences 2. <i>Frontiers in Medicine</i> , 2022, 9, 813964.	1.2	0
1320	Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 500-513.	2.3	8
1321	6 month serologic response to the Pfizer-BioNTech COVID-19 vaccine among healthcare workers. <i>PLoS ONE</i> , 2022, 17, e0266781.	1.1	4
1322	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 797918.	2.2	1

#	ARTICLE	IF	CITATIONS
1323	A Highly Potent SARS-CoV-2 Blocking Lectin Protein. <i>ACS Infectious Diseases</i> , 2022, 8, 1253-1264.	1.8	20
1324	Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. <i>Journal of Virology</i> , 2022, 96, e0038922.	1.5	5
1325	COVID-19 Vaccines: Current and Future Perspectives. <i>Vaccines</i> , 2022, 10, 608.	2.1	26
1326	Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients. <i>European Journal of Immunology</i> , 2022, 52, 1297-1307.	1.6	37
1327	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	0.8	26
1328	COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 62, 77-88.	0.9	20
1330	The Immunogenicity and Safety of Three Types of SARS-CoV-2 Vaccines in Adult Patients with Immune-Mediated Inflammatory Diseases: A Longitudinal Cohort Study. <i>Biomedicines</i> , 2022, 10, 911.	1.4	9
1331	Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. <i>Viruses</i> , 2022, 14, 803.	1.5	10
1332	Higher Antibody Concentrations in U.S. Health Care Workers Associated with Greater Reactogenicity Post-Vaccination. <i>Vaccines</i> , 2022, 10, 601.	2.1	7
1333	Detecting SARS-CoV-2 neutralizing immunity: highlighting the potential of split nanoluciferase technology. <i>Journal of Molecular Cell Biology</i> , 2022, 14, .	1.5	4
1334	Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis. <i>Frontiers in Public Health</i> , 2022, 10, 829176.	1.3	25
1336	Attitudes of COVID-19 vaccination among college students: A systematic review and meta-analysis of willingness, associated determinants, and reasons for hesitancy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-13.	1.4	16
1337	Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination. <i>Vaccines</i> , 2022, 10, 640.	2.1	0
1338	Nano-vectors for CRISPR/Cas9-mediated genome editing. <i>Nano Today</i> , 2022, 44, 101482.	6.2	15
1339	Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103800.	0.9	4
1340	Targeting strategies for mRNA delivery. <i>Materials Today Advances</i> , 2022, 14, 100240.	2.5	15
1341	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
1342	Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2022, 57, 1183-1186.	1.3	6

#	ARTICLE	IF	CITATIONS
1343	Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	1.4	14
1344	Editorial: microRNAs for the diagnosis of fatty liver disease in the population—are we inching closer towards the target? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 559-560.	1.9	0
1346	SARS-CoV-2 seroprevalence among healthcare workers. <i>PLoS ONE</i> , 2022, 17, e0266410.	1.1	14
1348	SARS-CoV-2 infection: efficacy of extensive vaccination of the healthcare workforce in a large Italian hospital.. <i>Medicina Del Lavoro</i> , 2021, 112, 465-476.	0.3	0
1349	Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection.. <i>Acta Biomedica</i> , 2022, 92, e2021464.	0.2	0
1350	Expression of Human ACE2 N-terminal Domain, Part of the Receptor for SARS-CoV-2, in Fusion With Maltose-Binding Protein, E. coli Ribonuclease I and Human RNase A. <i>Frontiers in Microbiology</i> , 2021, 12, 660149.	1.5	1
1351	Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. <i>Vaccines</i> , 2022, 10, 487.	2.1	4
1352	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
1353	SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2042-2056.	1.9	8
1354	Answering to social issues – Delivery of mRNA vaccines and therapeutics. <i>Drug Delivery System</i> , 2022, 37, 25-34.	0.0	0
1355	Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine. <i>Clinical and Translational Immunology</i> , 2022, 11, e1391.	1.7	21
1356	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
1357	Enabling community input to improve equity in and access to translational research: The Community Coalition for Equity in Research. <i>Journal of Clinical and Translational Science</i> , 2022, 6, .	0.3	2
1359	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	2.2	10
1360	Quality by Design for enabling RNA platform production processes. <i>Trends in Biotechnology</i> , 2022, 40, 1213-1228.	4.9	36
1361	A Short Series of Case Reports of COVID-19 in Immunocompromised Patients. <i>Viruses</i> , 2022, 14, 934.	1.5	4
1362	The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. <i>Vaccines</i> , 2022, 10, 712.	2.1	4
1363	Biocomposite-based nanostructured delivery systems for treatment and control of inflammatory lung diseases. <i>Nanomedicine</i> , 2022, , .	1.7	0

#	ARTICLE	IF	CITATIONS
1364	Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers. <i>Vaccines</i> , 2022, 10, 650.	2.1	4
1365	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	2.2	25
1366	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
1367	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. <i>Vaccines</i> , 2022, 10, 717.	2.1	15
1368	A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations. <i>Clinical Infectious Diseases</i> , 2022, 75, S30-S36.	2.9	7
1369	Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review. <i>Immunological Medicine</i> , 2022, 45, 225-237.	1.4	18
1370	Emerging SARS-CoV-2 variants: Why, how, and what's next?. , 2022, 1, 100029.		26
1371	COVID-19 vaccine dosage in children, adolescents, and young adults " is less more?. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0
1372	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
1373	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) Tj ETQq1 1 0.784314 rgBT ³ Overlo	0.8	1
1374	The clinical progress of mRNA vaccines and immunotherapies. <i>Nature Biotechnology</i> , 2022, 40, 840-854.	9.4	248
1375	A Review of Different Vaccines and Strategies to Combat COVID-19. <i>Vaccines</i> , 2022, 10, 737.	2.1	8
1376	Markers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan. <i>Frontiers in Immunology</i> , 2022, 13, 836923.	2.2	5
1377	Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 730-737.	1.8	1
1378	Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection. , 2022, 1, .		6
1379	Antibody-mediated neutralization of SARS-CoV-2. <i>Immunity</i> , 2022, 55, 925-944.	6.6	74
1380	Methodological Issues in Using a Common Data Model of COVID-19 Vaccine Uptake and Important Adverse Events of Interest: Feasibility Study of Data and Connectivity COVID-19 Vaccines Pharmacovigilance in the United Kingdom. <i>JMIR Formative Research</i> , 2022, 6, e37821.	0.7	4
1381	A case of an elderly female who developed subacute pleuropericarditis following BNT162b2 mRNA COVID-19 vaccination. <i>Journal of Cardiology Cases</i> , 2022, , .	0.2	3

#	ARTICLE	IF	CITATIONS
1382	Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 24, 100474.	1.3	13
1383	Structure-guided affinity maturation of a novel human antibody targeting the SARS-CoV-2 nucleocapsid protein. <i>Scientific Reports</i> , 2022, 12, 8469.	1.6	3
1384	Diagnosis of COVID-19 in symptomatic patients: An updated review. <i>Vacunas (English Edition)</i> , 2022, 23, 55-61.	0.3	0
1385	When and How Will the Epidemic of COVID-19 End?. , 2022, 13, 641.		4
1386	Evoluci3n de pacientes hospitalizados durante la pandemia de COVID-19 en Per3. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
1388	Immunological heterogeneity informs estimation of the durability of vaccine protection. <i>Journal of the Royal Society Interface</i> , 2022, 19, .	1.5	2
1389	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1
1390	Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	9
1391	Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. <i>Lancet Respiratory Medicine</i> , 2022, 10, 749-760.	5.2	65
1392	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. <i>Pharmaceutics</i> , 2022, 14, 1101.	2.0	15
1393	Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1391-1414.	1.8	8
1394	Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. <i>Vaccines</i> , 2022, 10, 799.	2.1	13
1395	Identification of SARS-CoV-2 by Gold Nanoparticles. <i>Biocell</i> , 2022, .	0.4	0
1396	Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
1397	mRNA-based therapies: Preclinical and clinical applications. <i>International Review of Cell and Molecular Biology</i> , 2022, , 1-54.	1.6	7
1398	Humoral and cellular immune memory to four COVID-19 vaccines. <i>Cell</i> , 2022, 185, 2434-2451.e17.	13.5	289
1399	mRNA-based therapeutics: powerful and versatile tools to combat diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	160
1400	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5

#	ARTICLE	IF	CITATIONS
1401	Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. <i>Vaccines</i> , 2022, 10, 801.	2.1	13
1402	Comparison of Four Systems for SARS-CoV-2 Antibody at Three Time Points after SARS-CoV-2 Vaccination. <i>Diagnostics</i> , 2022, 12, 1349.	1.3	0
1404	Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 500-505.	0.6	2
1406	Paving the Way Towards Precision Vaccinology: The Paradigm of Myocarditis After Coronavirus Disease 2019 (COVID-19) Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 75, S18-S23.	2.9	2
1407	Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate. <i>Vaccines</i> , 2022, 10, 897.	2.1	5
1408	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2796.	1.7	9
1409	COVID-19 vaccine design using reverse and structural vaccinology, ontology-based literature mining and machine learning. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	4
1411	One-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach. <i>Canadian Geriatrics Journal</i> , 2022, 25, 212-221.	0.7	0
1412	A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory. <i>Viruses</i> , 2022, 14, 1211.	1.5	8
1414	Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study. <i>Journal of Medical Virology</i> , 2022, 94, 4719-4726.	2.5	6
1415	Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. <i>Journal of Controlled Release</i> , 2022, 348, 84-94.	4.8	82
1416	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. <i>Current Opinion in Immunology</i> , 2022, 77, 102214.	2.4	7
1417	Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2022, 109, 108906.	1.7	43
1418	Neuroretinitis after the second injection of a SARS-CoV-2-vaccine: A case report. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 27, 101592.	0.4	8
1419	Advances in Circular RNA and Its Applications. <i>International Journal of Medical Sciences</i> , 2022, 19, 975-985.	1.1	46
1420	Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2022, 16, 117954842211053.	0.5	3
1421	Antibody testing as the guide to our living with COVID-19. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2022, 33, 338-346.	0.1	0
1422	Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models. <i>Molecular Immunology</i> , 2022, 149, 107-118.	1.0	2

#	ARTICLE	IF	CITATIONS
1423	Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1425	Making COVID-19 mRNA vaccines accessible: challenges resolved. <i>Expert Review of Vaccines</i> , 2022, 21, 1163-1176.	2.0	6
1426	Tachycardia following Pfizer-BioNTech COVID-19 vaccine. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022, , .	0.3	4
1427	Immune system changes in those with hypertension when infected with SARS-CoV-2. <i>Cellular Immunology</i> , 2022, 378, 104562.	1.4	2
1428	Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. , 2022, 1, 100002.		34
1429	Acute necrotic disorder of the small intestine postâ€coronavirus diseaseâ€2019 vaccination. <i>DEN Open</i> , 2023, 3, .	0.5	0
1430	Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1431	Is Measurement of Systemic IgG Antibodies the Wrong Way to Assess COVID-19 Vaccine Effectiveness for Breakthrough Infections?. <i>Journal of applied laboratory medicine</i> , The, 0, , .	0.6	0
1433	Immunizing the imperfect immune system. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 562-571.e1.	0.5	16
1434	Comparative Profiles of SARS-CoV-2 Spike-Specific Human Milk Antibodies Elicited by mRNA- and Adenovirus-Based COVID-19 Vaccines. <i>Breastfeeding Medicine</i> , 2022, 17, 638-646.	0.8	11
1435	Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1436	Immune Response to SARS-CoV-2 Vaccines. <i>Biomedicines</i> , 2022, 10, 1464.	1.4	24
1437	Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
1438	Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts. <i>Journal of Virological Methods</i> , 2022, 307, 114569.	1.0	6
1439	Performance of Whole Blood Stimulation Assays for the Quantification of SARS-CoV-2 Specific T-Cell Response: A Cross-Sectional Study. <i>Diagnostics</i> , 2022, 12, 1509.	1.3	2
1440	Global prevalence and clinical manifestations of cutaneous adverse reactions following COVIDâ€19 vaccination: A systematic review and metaâ€analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1947-1968.	1.3	26
1441	Severe acute respiratory syndrome coronavirus 2 variantsâ€Possibility of universal vaccine design: A review. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3533-3544.	1.9	3
1442	The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis. <i>Chinese Medicine</i> , 2022, 17, .	1.6	9

#	ARTICLE	IF	CITATIONS
1443	Is the COVID-19 Pandemic Over? The Current Status of Boosters, Immunosenescence, Long Haul COVID, and Systemic Complications. <i>International Journal of Translational Medicine</i> , 2022, 2, 230-241.	0.1	0
1444	Immunological Study of Combined Administration of SARS-CoV-2 DNA Vaccine and Inactivated Vaccine. <i>Vaccines</i> , 2022, 10, 929.	2.1	3
1445	mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19. <i>Microorganisms</i> , 2022, 10, 1250.	1.6	2
1446	Safety evaluation of the single-dose Ad26.COVS vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. <i>PLoS Medicine</i> , 2022, 19, e1004024.	3.9	10
1447	Giant cell myocarditis after first dose of BNT162b2 – a case report. <i>European Journal of Heart Failure</i> , 2022, 24, 1319-1322.	2.9	4
1448	The Race for COVID-19 Vaccines: The Various Types and Their Strengths and Weaknesses. <i>Journal of Pharmacy Practice</i> , 2023, 36, 953-966.	0.5	6
1449	Humoral response to anti-SARS-CoV-2 vaccine in breastfeeding mothers and mother-to-infant antibody transfer through breast milk. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8
1450	A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. <i>Translational Research</i> , 2022, 249, 13-27.	2.2	5
1451	Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro. <i>Biomacromolecules</i> , 2022, 23, 2976-2988.	2.6	5
1452	Antimelanoma Differentiation-Associated Gene 5 Antibody – Positive Interstitial Lung Disease After Vaccination With COVID-19 mRNA Vaccines. <i>Journal of Rheumatology</i> , 2022, 49, 1158-1162.	1.0	8
1453	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	63
1454	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
1456	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. <i>Vaccine</i> , 2022, 40, 4220-4230.	1.7	27
1457	Nanomaterial-based delivery of vaccine through nasal route: Opportunities, challenges, advantages, and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103533.	1.4	12
1458	Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan. <i>Vaccine: X</i> , 2022, 11, 100173.	0.9	1
1459	SARS-CoV-2 antibody response after BNT162b2 mRNA vaccine in healthcare workers: Nine-month of follow-up. <i>Vaccine: X</i> , 2022, 11, 100175.	0.9	5
1460	Anti-viral memory T cell responses in the absence of IgG production in a COVID-19 convalescent individual. , 2022, 1, 20220009.		1
1461	Applications of nanoengineered therapeutics and vaccines: special emphasis on COVID-19. , 2022, , 21-63.		0

#	ARTICLE	IF	CITATIONS
1462	mRNA delivery technologies: Toward clinical translation. <i>International Review of Cell and Molecular Biology</i> , 2022, , 207-293.	1.6	5
1463	Transport and optimal control of vaccination dynamics for COVID-19. , 2022, , 27-39.		1
1464	Evaluation of the Effects of mRNA and Inactive COVID Vaccine Applications on the Clinical Course of COVID 19 Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1465	Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1466	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
1467	Comparison of COVID-19 Vaccines Introduced in Korea. <i>Biomedical Science Letters</i> , 2022, 28, 67-82.	0.0	1
1468	Evaluation of Immunogenicity and Safety of Vero Cell-Derived Inactivated COVID-19 Vaccine in Older Patients with Hypertension and Diabetes Mellitus. <i>Vaccines</i> , 2022, 10, 1020.	2.1	12
1469	mRNA vaccines: Past, present, future. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 491-522.	4.3	24
1470	An Overview on Immunity Booster Foods in Coronavirus Disease (COVID-19). <i>Combinatorial Chemistry and High Throughput Screening</i> , 2023, 26, 1251-1284.	0.6	1
1471	Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. <i>Vaccines</i> , 2022, 10, 1031.	2.1	6
1472	Safety and Immunogenicity of Inactivated <i>Bacillus subtilis</i> Spores as a Heterologous Antibody Booster for COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1014.	2.1	4
1473	Effect of Sinovac or Biontech Vaccination on Mortality in COVID-19 Patients in The Intensive Care Unit. <i>European Journal of Education and Pedagogy</i> , 2022, 3, 18-20.	0.2	0
1474	Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. <i>Npj Vaccines</i> , 2022, 7, .	2.9	7
1475	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. <i>Advances in Therapy</i> , 2022, 39, 3789-3798.	1.3	3
1476	Immunogenicity and efficacy of Ad26.<sc>COV2</sc>.S: An adenoviral vectorâ€‘based <sc>COVID</sc>â€‘19 vaccine. <i>Immunological Reviews</i> , 2022, 310, 47-60.	2.8	10
1477	Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1479	Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination. <i>Biomedicines</i> , 2022, 10, 1641.	1.4	3
1480	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	23

#	ARTICLE	IF	CITATIONS
1481	Engineering circular RNA for enhanced protein production. <i>Nature Biotechnology</i> , 2023, 41, 262-272.	9.4	83
1482	Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1644-1648.	2.8	6
1483	A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, 44, 102584.	1.7	7
1484	Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs. <i>Nature Communications</i> , 2022, 13, .	5.8	53
1485	Trimeric receptor-binding domain of SARS-CoV-2 acts as a potent inhibitor of ACE2 receptor-mediated viral entry. <i>IScience</i> , 2022, 25, 104716.	1.9	6
1486	Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination. <i>European Journal of Haematology</i> , 2022, 109, 458-464.	1.1	9
1487	Donor-directed immunologic safety of COVID-19 vaccination in renal transplant recipients. <i>Human Immunology</i> , 2022, 83, 607-612.	1.2	3
1488	Durability of SARS-CoV-2 Specific IgG Antibody Responses Following Two Doses of Match and Mixed COVID-19 Vaccines Regimens in Saudi Population. <i>Infection and Drug Resistance</i> , 0, Volume 15, 3791-3800.	1.1	4
1489	New-onset pemphigus vegetans and pemphigus foliaceus after SARS-CoV-2 vaccination: A report of 2 cases. <i>JAAD Case Reports</i> , 2022, 27, 94-98.	0.4	5
1490	Model-Based Evaluation of Transmissibility and Intervention Measures for a COVID-19 Outbreak in Xiamen City, China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
1491	Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. <i>Emerging Microbes and Infections</i> , 2022, 11, 1828-1832.	3.0	32
1492	Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. <i>BMJ Open</i> , 2022, 12, e060425.	0.8	9
1493	Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 1069.	2.1	2
1494	Neutralizing Antibodies to Human Cytomegalovirus Recombinant Proteins Reduce Infection in an Ex Vivo Model of Developing Human Placentas. <i>Vaccines</i> , 2022, 10, 1074.	2.1	2
1495	COVID-19 and plasma cells: Is there long-lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
1497	Inhalable dry powder mRNA vaccines based on extracellular vesicles. <i>Matter</i> , 2022, 5, 2960-2974.	5.0	75
1498	Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines. <i>Biomedicines</i> , 2022, 10, 1676.	1.4	5
1499	COVID-19 vaccination in people with multiple sclerosis, real-life experience. <i>Clinical Neurology and Neurosurgery</i> , 2022, 220, 107374.	0.6	6

#	ARTICLE	IF	CITATIONS
1500	Pharmacokinetic Study of Coadministration with Cefuroxime Sodium for Injection Influencing ReDuNing Injection-Derived Seven Phytochemicals and Nine Metabolites in Rats. <i>Journal of Analytical Methods in Chemistry</i> , 2022, 2022, 1-17.	0.7	3
1501	Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1301-1318.	2.0	12
1502	Anaphylaxis and Related Events Following COVID-19 Vaccination: A Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1335-1349.	1.0	4
1503	Lipid nanoparticles in the development of mRNA vaccines for COVID-19. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 74, 103553.	1.4	44
1504	Acceptance Rates of COVID-19 Vaccine Highlight the Need for Targeted Public Health Interventions. <i>Vaccines</i> , 2022, 10, 1167.	2.1	3
1505	SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies. <i>American Journal of Hematology</i> , 2022, 97, 1300-1308.	2.0	12
1506	Why does COVID-19 continue to spread despite mass vaccination?. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1507	A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1508	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. <i>Science</i> , 2022, 377, 890-894.	6.0	142
1509	Effectiveness of Comirnaty® Vaccine and Correlates of Immunogenicity and Adverse Reactions: A Single-Center Prospective Case Series Study. <i>Vaccines</i> , 2022, 10, 1170.	2.1	2
1510	SARS-CoV-2's Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
1511	Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial. <i>EClinicalMedicine</i> , 2022, 51, 101569.	3.2	58
1513	Case Series of Myocarditis Following mRNA COVID Vaccine Compared to Pediatric Multisystem Inflammatory Syndrome: Multicenter Retrospective Study. <i>Vaccines</i> , 2022, 10, 1207.	2.1	3
1514	Recent Updates on mRNA Vaccines. <i>Vaccines</i> , 2022, 10, 1209.	2.1	1
1515	BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves. <i>Journal of Neurology</i> , 2022, 269, 6193-6201.	1.8	12
1516	Side Effects of COVID-19 Vaccines (Pfizer, AstraZeneca) in Saudi Arabia, Eastern Province. <i>Cureus</i> , 2022, , .	0.2	7
1517	Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. <i>Npj Vaccines</i> , 2022, 7, .	2.9	13
1518	Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10

#	ARTICLE	IF	CITATIONS
1519	Case Report: Subacute thyroiditis after receiving inactivated SARS-CoV-2 vaccine (BBIBP-CoV). <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1520	Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. <i>Gut</i> , 2023, 72, 295-305.	6.1	29
1521	Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2. <i>Viruses</i> , 2022, 14, 1553.	1.5	9
1522	Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	3
1523	Recent progress in application of nanovaccines for enhancing mucosal immune responses. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 2334-2345.	5.7	6
1524	A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	4
1525	Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection. <i>Vaccine</i> , 2022, 40, 5726-5731.	1.7	11
1526	Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 1993.	1.4	8
1527	COVID-19 and vaccination: myths vs science. <i>Expert Review of Vaccines</i> , 2022, 21, 1603-1620.	2.0	23
1528	Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: A systematic review and meta-analysis protocol. <i>PLoS ONE</i> , 2022, 17, e0272839.	1.1	5
1529	Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections. <i>MBio</i> , 2022, 13, .	1.8	7
1530	Potential of mRNA vaccines to become versatile cancer vaccines. <i>World Journal of Clinical Oncology</i> , 2022, 13, 663-674.	0.9	1
1531	Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response. <i>Clinical Research in Cardiology</i> , 2023, 112, 1506-1516.	1.5	2
1532	mRNA vaccines in the prevention and treatment of diseases. <i>MedComm</i> , 2022, 3, .	3.1	14
1533	Nanoparticles in clinical trials of COVID-19: An update. <i>International Journal of Surgery</i> , 2022, 104, 106818.	1.1	22
1534	Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. <i>Human Immunology</i> , 2022, 83, 755-767.	1.2	10
1535	COVID-19 Vaccine Clinical Trials: A Bird's Eye Perspective. <i>Cureus</i> , 2022, , .	0.2	0
1536	Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7

#	ARTICLE	IF	CITATIONS
1537	Immunosenescence, aging and successful aging. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	35
1538	Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples. <i>Scientific World Journal, The</i> , 2022, 2022, 1-7.	0.8	2
1539	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1540	Vibropolyfection: coupling polymer-mediated gene delivery to mechanical stimulation to enhance transfection of adherent cells. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	2
1541	SARS-CoV-2 pre-exposure prophylaxis: A potential COVID-19 preventive strategy for high-risk populations, including healthcare workers, immunodeficient individuals, and poor vaccine responders. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
1542	Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 78-81.	0.8	1
1543	Epidemiological aspects of headache after different types of COVID-19 vaccines: An online survey. <i>Headache</i> , 2022, 62, 1046-1052.	1.8	5
1544	Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e061584.	0.8	4
1545	SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8982.	1.8	4
1546	Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross-sectional survey in Northwest Ethiopia. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
1547	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1548	Neutralizing Antibody Response, Safety, and Efficacy of mRNA COVID-19 Vaccines in Pediatric Patients with Inflammatory Bowel Disease: A Prospective Multicenter Case-Control Study. <i>Vaccines</i> , 2022, 10, 1265.	2.1	6
1549	Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategies. <i>Journal of Medical Virology</i> , 2022, 94, 5841-5849.	2.5	7
1550	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
1551	Efficacy and safety of COVID-19 vaccines: A network meta-analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	0.7	14
1552	The current status of COVID-19 vaccines. A scoping review. <i>Drug Discovery Today</i> , 2022, 27, 103336.	3.2	7
1553	Modeling of MT. P495, an mRNA-based vaccine against the phosphate-binding protein PstS1 of <i>Mycobacterium tuberculosis</i> . <i>Molecular Diversity</i> , 2023, 27, 1613-1632.	2.1	4
1554	Emerging trends of research on mRNA vaccines: A co-citation analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1

#	ARTICLE	IF	CITATIONS
1555	Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. <i>Cell Reports</i> , 2022, 40, 111214.	2.9	24
1557	Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 196.	0.9	32
1558	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
1559	Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people. <i>JCI Insight</i> , 2022, 7, .	2.3	10
1560	Antibody response after first and second BNT162b2 vaccination to predict the need for subsequent injections in nursing home residents. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1561	Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
1562	New-onset IgA nephropathy following COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 26-39.	0.2	20
1563	A platform technology for generating subunit vaccines against diverse viral pathogens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1564	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
1565	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5
1566	Determining the Health Problems Experienced by Young Adults in Turkey, Who Received the COVID-19 Vaccine. <i>Vaccines</i> , 2022, 10, 1526.	2.1	1
1567	Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination. , 2022, 2, 196-206.		6
1568	Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
1569	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
1570	Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	7
1571	A BRIEF DESCRIPTION OF COVID-19 PULMONARY VIRAL INFECTION AND REPURPOSING OF DRUGS FOR ITS TREATMENT. <i>International Journal of Applied Pharmaceutics</i> , 0, , 22-31.	0.3	1
1572	Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study. <i>Lancet Regional Health - Europe</i> , The, 2022, 21, 100478.	3.0	10
1573	Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach. <i>EBioMedicine</i> , 2022, 84, 104264.	2.7	4

#	ARTICLE	IF	CITATIONS
1574	Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. <i>EBioMedicine</i> , 2022, 84, 104271.	2.7	1
1575	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
1576	Comparison of SARS-CoV-2 spike antibody quantitative titer reporting using the World Health Organization International Standard Units by four commercial assays. <i>Journal of Clinical Virology</i> , 2022, 156, 105292.	1.6	6
1577	Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 29, 100586.	1.3	6
1578	Recent advances in nanotechnology approaches for non-viral gene therapy. <i>Biomaterials Science</i> , 2022, 10, 6862-6892.	2.6	15
1579	Salivary SARS-CoV-2 antibody detection using S1-RBD protein-immobilized 3D melt electrowritten poly(μ -caprolactone) scaffolds. <i>RSC Advances</i> , 2022, 12, 24849-24856.	1.7	7
1580	Nature of viruses and pandemics: Coronaviruses. <i>Current Research in Immunology</i> , 2022, 3, 151-158.	1.2	3
1581	Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults. <i>Infection and Chemotherapy</i> , 2022, 54, 504.	1.0	2
1582	Review the safety and efficacy of vaccines under the condition of COVID-19 epidemic. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
1583	Clinical Development of mRNA Vaccines: Challenges and Opportunities. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 167-186.	0.7	2
1584	Minimal change disease and COVID-19 vaccination: Four cases and review of literature. <i>Clinical Nephrology Case Studies</i> , 2022, 10, 54-63.	0.3	7
1585	Messenger RNA Therapeutics: Start of a New Era in Medicine. <i>RNA Technologies</i> , 2022, , 41-71.	0.2	0
1586	Optimal design and planning of supply chains for viral vectors and RNA vaccines. <i>Computer Aided Chemical Engineering</i> , 2022, , 1633-1638.	0.3	2
1587	Keratoplasty rejection after messenger RNA vaccine (BNT162b2) for COVID-19. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 3134.	0.5	3
1588	Epidemiology of COVID-19 Outbreaks in Aged Care Facilities During Post-Vaccine Period: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1589	SARS-COV-2 and Other mRNA Vaccines. <i>RNA Technologies</i> , 2022, , 113-138.	0.2	0
1590	Immunological Changes. <i>Lessons From the ICU</i> , 2022, , 69-90.	0.1	0
1591	Prevalence and factors associated with COVID-19 vaccine acceptance among the general population in Asadabad, Iran: a cross-sectional study. <i>Tropical Medicine and Health</i> , 2022, 50, .	1.0	2

#	ARTICLE	IF	CITATIONS
1592	Antibodies against SARS-CoV-2 Alpha, Beta, and Gamma Variants in Pregnant Women and Their Neonates under Antenatal Vaccination with Moderna (mRNA-1273) Vaccine. <i>Vaccines</i> , 2022, 10, 1415.	2.1	6
1593	Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents. <i>British Journal of Haematology</i> , 2022, 199, 549-559.	1.2	9
1594	Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination. <i>Cancers</i> , 2022, 14, 4464.	1.7	7
1595	Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion. <i>PLoS Pathogens</i> , 2022, 18, e1010830.	2.1	11
1596	Association of Influenza Vaccination With SARS-CoV-2 Infection and Associated Hospitalization and Mortality Among Patients Aged 66 Years or Older. <i>JAMA Network Open</i> , 2022, 5, e2233730.	2.8	19
1597	Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
1598	Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 1202-1209.	0.9	10
1599	A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects. <i>PLoS ONE</i> , 2022, 17, e0274553.	1.1	3
1601	A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons. <i>European Journal of Heart Failure</i> , 2023, 25, 313-318.	2.9	8
1602	A Cellular Assay for Spike/ACE2 Fusion: Quantification of Fusion-Inhibitory Antibodies after COVID-19 and Vaccination. <i>Viruses</i> , 2022, 14, 2118.	1.5	1
1604	Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1606	Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100752.	3.3	14
1607	Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1609	Humoral immunoresponse elicited against an adenoviral-based SARS-CoV-2 coronavirus vaccine in elderly patients. <i>Aging</i> , 2022, 14, 7193-7205.	1.4	2
1611	A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines. <i>DARU, Journal of Pharmaceutical Sciences</i> , 0, , .	0.9	5
1612	Long-term memory CD8+ T cells specific for SARS-CoV-2 in individuals who received the BNT162b2 mRNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1613	Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. <i>Exploration of Immunology</i> , 2022, 2, 648-664.	1.7	1
1615	Sinopharm's BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1462.	2.1	5

#	ARTICLE	IF	CITATIONS
1617	Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. <i>Science Advances</i> , 2022, 8, .	4.7	22
1618	Two Cases of Autoimmune Thyroid Disorders after COVID Vaccination in Dialysis Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11492.	1.8	3
1619	Shedding of infectious SARS-CoV-2 despite vaccination. <i>PLoS Pathogens</i> , 2022, 18, e1010876.	2.1	36
1620	A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	3
1621	Investigation of Possible Factors Influencing the Neutralizing Anti-SARS-CoV-2 Antibody Titer after Six Months from the Second Vaccination Dose in a Sample of Italian Nursing Home Personnel. <i>Antibodies</i> , 2022, 11, 59.	1.2	3
1623	Effects of the BNT162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 0, , .	0.8	5
1624	How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10374.	1.8	10
1625	Formulation of Lipid-Free Polymeric Mesoscale Nanoparticles Encapsulating mRNA. <i>Pharmaceutical Research</i> , 2022, 39, 2699-2707.	1.7	1
1627	SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≥60 years: One year of surveillance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1628	Answers to common questions about COVID-19 vaccines in children with cancer. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	0.8	3
1629	SARS-CoV-2 in immunocompromised individuals. <i>Immunity</i> , 2022, 55, 1779-1798.	6.6	50
1630	Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients. <i>Clinical Rheumatology</i> , 2022, 41, 3879-3885.	1.0	5
1631	Longitudinal neutralization activities on authentic Omicron variant provided by 3 doses of BBIBP-CorV vaccination during one year. <i>Proteomics</i> , 0, , 2200306.	1.3	2
1632	Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-coronavirus, and pan-2-coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
1633	The bullwhip effect, T-cell telomeres, and SARS-CoV-2. <i>The Lancet Healthy Longevity</i> , 2022, 3, e715-e721.	2.0	2
1634	Vaccine-induced seroconversion in participants in the North Carolina COVID-19 community Research Partnership. <i>Vaccine</i> , 2022, 40, 6133-6140.	1.7	6
1635	Nanovaccines to combat virus-related diseases. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2023, 15, .	3.3	3
1636	Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2023, 76, 201-209.	2.9	10

#	ARTICLE	IF	CITATIONS
1637	Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. <i>Nature Communications</i> , 2022, 13, .	5.8	15
1638	Engineering hybrid nanosystems for efficient and targeted delivery against bacterial infections. <i>Journal of Controlled Release</i> , 2022, 351, 598-622.	4.8	17
1639	Antibody response to BNT162b2 mRNA vaccine in gingival crevicular fluid. <i>Journal of Periodontology</i> , 2023, 94, 77-87.	1.7	7
1641	Bioinformatic Analysis of SARS-CoV-2 Genomes to Develop a Universal Coronavirus Vaccine. <i>Journal of Biosciences and Medicines</i> , 2022, 10, 84-97.	0.1	0
1642	Neutralizing antibody response to COVID vaccination among the young and the elderly. <i>Journal of the Indian Academy of Geriatrics</i> , 2022, 18, 103.	0.0	0
1643	Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of <i>in vivo</i> imaging. <i>Theranostics</i> , 2022, 12, 7509-7531.	4.6	43
1644	Polymeric Micelles for Targeted Drug Delivery Systems. <i>Nanotechnology in the Life Sciences</i> , 2022, , 521-559.	0.4	0
1645	Seroprevalence of SARS-CoV-2 antibodies in vaccinated healthcare workers in Marrakech (Morocco). <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211336.	1.0	2
1646	Lipid nanoparticles for mRNA delivery. <i>Drug Delivery System</i> , 2022, 37, 237-246.	0.0	1
1647	Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. <i>Vaccines</i> , 2022, 10, 1646.	2.1	4
1648	SARS-CoV-2 vaccine strategies in kidney transplant recipients. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 263-264.	4.6	3
1649	Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study. <i>Viruses</i> , 2022, 14, 2361.	1.5	3
1650	Cell Entry and Unusual Replication of SARS-CoV-2. <i>Current Drug Targets</i> , 2022, 23, 1539-1554.	1.0	1
1651	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	2.1	12
1652	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
1653	Self-Amplifying RNA Approach for Protein Replacement Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12884.	1.8	13
1654	Efficacy and safety of four COVID-19 vaccines in preventing SARS-CoV-2 infection: A rapid review. <i>Biomedica</i> , 2022, 42, 19-31.	0.3	2
1655	Dose optimisation and scarce resource allocation: two sides of the same coin. <i>BMJ Open</i> , 2022, 12, e063436.	0.8	5

#	ARTICLE	IF	CITATIONS
1656	Analysis and comparison of anti-RBD neutralizing antibodies from AZD-1222, Sputnik V, Sinopharm and Covaxin vaccines and its relationship with gender among health care workers. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	5
1657	Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2. <i>Journal of Infectious Diseases</i> , 2023, 227, 353-363.	1.9	2
1659	Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	4
1660	Quantum Chemical Computation of Omicron Mutations Near Cleavage Sites of the Spike Protein. <i>Microorganisms</i> , 2022, 10, 1999.	1.6	4
1661	Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1807.	2.1	9
1662	SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	12
1663	Nucleic Acid Vaccines against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1849.	2.1	10
1664	Multiple Evanescent White Dot Syndrome Following COVID-19 mRNA Vaccination. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 1240-1244.	1.0	5
1665	Promising strategy for developing mRNA-based universal influenza virus vaccine for human population, poultry, and pigs focus on the bigger picture. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1666	Plant Molecular Pharming and Plant-Derived Compounds towards Generation of Vaccines and Therapeutics against Coronaviruses. <i>Vaccines</i> , 2022, 10, 1805.	2.1	3
1667	Strategy of developing nucleic acid-based universal monkeypox vaccine candidates. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
1668	Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	2.3	3
1669	Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 10-18.	0.6	5
1670	Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers. <i>Vaccines</i> , 2022, 10, 1809.	2.1	1
1671	Development of mRNA vaccines against respiratory syncytial virus (RSV). <i>Cytokine and Growth Factor Reviews</i> , 2022, 68, 37-53.	3.2	23
1672	Humoral and cellular immunity in patients with rare autoimmune rheumatic diseases following SARS-CoV-2 vaccination. <i>Rheumatology</i> , 2023, 62, 2294-2303.	0.9	3
1673	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. <i>Npj Vaccines</i> , 2022, 7, .	2.9	24
1674	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. <i>IScience</i> , 2022, 25, 105379.	1.9	4

#	ARTICLE	IF	CITATIONS
1675	Innate sensing of mRNA vaccines. <i>Current Opinion in Immunology</i> , 2022, 79, 102249.	2.4	4
1676	Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 15, 2369-2382.	0.8	12
1677	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. <i>Science Immunology</i> , 2022, 7, .	5.6	42
1679	COVID-19 Vaccination Perceptions Among Young Adults of Color in the San Francisco Bay Area. <i>Health Equity</i> , 2022, 6, 836-844.	0.8	3
1680	Serum Fc-Mediated Monocyte Phagocytosis Activity Is Stable for Several Months after SARS-CoV-2 Asymptomatic and Mildly Symptomatic Infection. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	4
1681	Success of nano-vaccines against COVID-19: a transformation in nanomedicine. <i>Expert Review of Vaccines</i> , 2022, 21, 1739-1761.	2.0	2
1682	Myositis unrelated to the inoculation site after COVID-19 vaccination: a case report. <i>Clinics in Shoulder and Elbow</i> , 0, , .	0.5	0
1683	Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individuals. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
1685	A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 2247-2257.	3.0	28
1686	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 27-45.	1.9	6
1687	COVID-19 vaccination in patients with cancer: Opportunities and challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1688	Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 687-704.	0.7	0
1689	Assessment of COVID-19 vaccination among healthcare workers in Iraq; adverse effects and hesitancy. <i>PLoS ONE</i> , 2022, 17, e0274526.	1.1	6
1690	Strong neutralizing antibody responses to SARS-CoV-2 variants following a single vaccine dose in subjects with previous SARS-CoV-2 infection. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	4
1691	CD4 and IL-2 mediated NK cell responses after COVID-19 infection and mRNA vaccination in adults. <i>Immunobiology</i> , 2023, 228, 152304.	0.8	2
1692	Recent advances of nanotechnology in COVID 19: A critical review and future perspective. <i>OpenNano</i> , 2023, 9, 100118.	1.8	0
1693	Evaluation of the Effect of Änfection and Ämmunity on the Tear Film by Scheimpflug-Placido Disc Topography- A Case Control Study. <i>Photodiagnosis and Photodynamic Therapy</i> , 2023, 41, 103216.	1.3	1
1694	COVID-19 signalome: Potential therapeutic interventions. <i>Cellular Signalling</i> , 2023, 103, 110559.	1.7	5

#	ARTICLE	IF	CITATIONS
1695	Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients. <i>Clinical Immunology Communications</i> , 2023, 3, 1-5.	0.5	1
1696	COVID-19 vaccines: Update of the vaccines in use and under development. <i>Vacunas (English Edition)</i> , 2022, 23, S88-S102.	0.3	0
1699	Developing New Tools to Fight Human Pathogens: A Journey through the Advances in RNA Technologies. <i>Microorganisms</i> , 2022, 10, 2303.	1.6	1
1701	Immunogenicity of the Two mRNA SARS-CoV-2 Vaccines in a Large Cohort of Dialysis Patients. <i>Infectious Disease Reports</i> , 2022, 14, 946-954.	1.5	1
1702	Current state of, prospects for, and obstacles to mRNA vaccine development. <i>Drug Discovery Today</i> , 2023, 28, 103458.	3.2	5
1703	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. <i>Vaccines</i> , 2022, 10, 2035.	2.1	3
1704	Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenström's Macroglobulinemia after BNT162b2 Booster Vaccination. <i>Cancers</i> , 2022, 14, 5816.	1.7	14
1705	COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review. <i>Vaccines</i> , 2022, 10, 2039.	2.1	2
1706	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. <i>Stem Cell Reviews and Reports</i> , 0, , .	1.7	2
1707	SARS-CoV-2 antibody response to third dose vaccination in a healthy cohort. <i>Insights in Clinical and Cellular Immunology</i> , 2022, 6, 008-013.	0.1	1
1708	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1709	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
1710	Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. <i>European Journal of General Practice</i> , 2023, 29, .	0.9	2
1711	mRNA therapy for myocardial infarction: A review of targets and delivery vehicles. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1713	Side Effects of COVID-19 Vaccines Primer Doses: Experience of Saudi Healthcare Workers Participating in CoVaST-SA. <i>Vaccines</i> , 2022, 10, 2137.	2.1	2
1714	Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs after Vaccination (DANTE-SIRIO 7) Study in a Large Cohort of Healthcare Workers. <i>Vaccines</i> , 2022, 10, 2125.	2.1	0
1718	Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer. <i>Human Cell</i> , 2023, 36, 493-514.	1.2	2
1719	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. <i>Expert Review of Vaccines</i> , 2023, 22, 35-53.	2.0	8

#	ARTICLE	IF	CITATIONS
1720	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. <i>International Immunology</i> , 2023, 35, 213-220.	1.8	6
1721	Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment. <i>Respiratory Investigation</i> , 2022, , .	0.9	1
1722	COVID-19 vaccination and liver disease. <i>World Journal of Gastroenterology</i> , 0, 28, 6791-6810.	1.4	6
1723	Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 6198-6207.	2.5	9
1724	Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA-1273. <i>Microbiology and Immunology</i> , 2023, 67, 120-128.	0.7	3
1725	Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum. <i>Pathogens</i> , 2022, 11, 1531.	1.2	2
1726	Antibody responses to COVID-19 vaccination in people with obesity: A systematic review and meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2023, 17, .	1.5	14
1727	COVID-19 Vaccines, Effectiveness, and Immune Responses. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15415.	1.8	9
1728	Protease-Independent Production of Poliovirus Virus-like Particles in <i>Pichia pastoris</i> : Implications for Efficient Vaccine Development and Insights into Capsid Assembly. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	2
1729	COVID-19 Vaccine Acceptance Among Pregnant and Lactating Women in Saudi Arabia. <i>Cureus</i> , 2022, , .	0.2	4
1730	mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics. <i>Vaccines</i> , 2022, 10, 2150.	2.1	25
1731	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
1733	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
1734	Effectiveness of Pfizer-BioNTech COVID-19 vaccine as evidence for policy action: A rapid systematic review and meta-analysis of non-randomized studies. <i>PLoS ONE</i> , 2022, 17, e0278624.	1.1	3
1735	Reverse genetic systems of SARS-CoV-2 for antiviral research. <i>Antiviral Research</i> , 2023, 210, 105486.	1.9	12
1736	Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
1738	THE MAIN ASPECTS OF COUNTERING PANDEMIC INFECTIOUS DISEASES THROUGH VACCINATION IN THE CONTEXT OF PROTECTING HEALTH AND OVERCOMING PSYCHOLOGICAL BARRIERS. <i>Wiadomości Lekarskie</i> , 2022, 75, 2785-2790.	0.1	0
1739	Endosomal sorting results in a selective separation of the protein corona from nanoparticles. <i>Nature Communications</i> , 2023, 14, .	5.8	9

#	ARTICLE	IF	CITATIONS
1740	Engineer RNA-Protein Nanowires as Light-Responsive Biomaterials. <i>Small</i> , 2023, 19, .	5.2	2
1741	Tachycardia following Pfizer-BioNTech COVID-19 vaccine. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2023, 41, 62-63.	0.2	0
1742	Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus-19 vaccine-associated lymphadenopathy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 0, , .	1.3	2
1744	Liver dysfunction-related COVID-19: A narrative review. <i>World Journal of Meta-analysis</i> , 0, 11, 5-17.	0.1	0
1745	Acidification-Induced Structure Evolution of Lipid Nanoparticles Correlates with Their <i><i>In Vitro</i></i> Gene Transfections. <i>ACS Nano</i> , 2023, 17, 979-990.	7.3	15
1746	The Situation of Students' COVID-19 Vaccination and Their Views on Vaccination: Turkey Case. <i>Modern Care Journal</i> , 2023, In Press, .	0.2	0
1747	Drug-induced sarcoidosis-like reaction three months after BNT162b2 mRNA COVID-19 vaccination: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 0, 11, 177-186.	0.3	1
1748	Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	0
1749	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. <i>Biomedical Journal</i> , 2023, 46, 70-80.	1.4	8
1750	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. <i>Vaccines</i> , 2023, 11, 101.	2.1	14
1751	Current Evidence on Vaccinations in Pediatric and Adult Patients with Systemic Autoinflammatory Diseases. <i>Vaccines</i> , 2023, 11, 151.	2.1	4
1752	Investigation of macromolecular transport through tunable collagen hyaluronic acid matrices. <i>Colloids and Surfaces B: Biointerfaces</i> , 2023, 222, 113123.	2.5	1
1753	Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 361-381.	0.2	2
1754	Skin manifestations following anti-COVID-19 vaccination: A multicentric study from Turkey. <i>Journal of Cosmetic Dermatology</i> , 2023, 22, 354-363.	0.8	3
1755	Herpes Zoster Following COVID-19 Vaccine Booster. <i>American Journal of Case Reports</i> , 0, 24, .	0.3	1
1756	Multimorbidity and Its Effect on Self-Reported Adverse Effects Following COVID-19 Vaccination. <i>Cureus</i> , 2022, , .	0.2	1
1757	Effectiveness of COVID-19 Vaccination with mRNA Vaccines for Patients with Cirrhosis in Hungary: Multicentre Matched Cohort Study. <i>Vaccines</i> , 2023, 11, 50.	2.1	2
1758	Nanotechnology for cosmetics applications—a journey in innovation. , 2023, , 263-278.		1

#	ARTICLE	IF	CITATIONS
1759	Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review. <i>Biology</i> , 2023, 12, 177.	1.3	11
1760	Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: A twelve-month follow-up study. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	7
1761	A Systematic Review on the Safety and Efficacy of COVID-19 Vaccines Approved in Saudi Arabia. <i>Vaccines</i> , 2023, 11, 281.	2.1	6
1762	Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 0, 56, .	0.4	2
1763	A hepatitis B virus core antigenâ€based virusâ€like particle vaccine expressing SARSâ€CoVâ€2 B and T cell epitopes induces epitopeâ€specific humoral and cellâ€mediated immune responses but confers limited protection against SARSâ€CoVâ€2 infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
1764	Altered cellular immune response to vaccination against SARS-CoV-2 in patients suffering from autoimmunity with B-cell depleting therapy. <i>Microbes and Infection</i> , 2023, 25, 105103.	1.0	1
1765	Neutralization activity of IgG antibody in COVIDâ€19â€convalescent plasma against SARS-CoV-2 variants. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
1766	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	14
1767	COVID-19 Breakthrough Infections in Vaccinated Patients With CLL in Israel. <i>HemaSphere</i> , 2023, 7, e839.	1.2	0
1771	Towards a Future of Personalized Vaccinology: Study on Individual Variables Influencing the Antibody Response to the COVID-19 Vaccine. <i>Vaccines</i> , 2023, 11, 217.	2.1	3
1772	A Comprehensive Review of mRNA Vaccines. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2700.	1.8	42
1773	Applications of genetic engineering in COVID-19. , 2023, , 219-237.		0
1774	First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCov2. <i>Lancet Microbe</i> , The, 2023, 4, e140-e148.	3.4	7
1775	Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1776	Current state-of-the-art review of nanotechnology-based therapeutics for viral pandemics: Special attention to COVID-19. <i>Nanotechnology Reviews</i> , 2023, 12, .	2.6	1
1777	SARS-CoV-2 Spike Protein Downregulates Cell Surface $\alpha 7$ nAChR through a Helical Motif in the Spike Neck. <i>ACS Chemical Neuroscience</i> , 2023, 14, 689-698.	1.7	3
1778	Assessment of immunostimulatory responses to the antimir-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
1779	Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity. <i>IScience</i> , 2023, 26, 106335.	1.9	5

#	ARTICLE	IF	CITATIONS
1780	No(cebo) Vax: COVID-19 Vaccine Beliefs Are Important Determinants of Both Occurrence and Perceived Severity of Common Vaccinesâ€™ Adverse Effects. <i>Psychological Science</i> , 0, , 095679762311638.	1.8	0
1781	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1782	Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease. <i>JHEP Reports</i> , 2023, 5, 100697.	2.6	7
1783	Development and applications of mRNA treatment based on lipid nanoparticles. <i>Biotechnology Advances</i> , 2023, 65, 108130.	6.0	10
1784	Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	1
1785	The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. <i>British Journal of Dermatology</i> , 2023, 188, 542-551.	1.4	1
1786	Potential health risks of mRNA-based vaccine therapy: A hypothesis. <i>Medical Hypotheses</i> , 2023, 171, 111015.	0.8	4
1787	Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1788	Comparison of the Immune Response After an Extended Primary Series of COVID-19 Vaccination in Kidney Transplant Recipients Receiving Standard Versus Mycophenolic Acidâ€™sparing Immunosuppressive Regimen. <i>Transplantation Direct</i> , 2022, 8, e1393.	0.8	1
1789	Highâ€™Precision Synthesis of RNAâ€™Loaded Lipid Nanoparticles for Biomedical Applications. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	11
1790	Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	3
1791	SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection. <i>Nature Communications</i> , 2023, 14, .	5.8	25
1792	Arrayed Imaging Reflectometry monitoring of anti-viral antibody production throughout vaccination and breakthrough Covid-19. <i>PLoS ONE</i> , 2023, 18, e0277846.	1.1	1
1794	Advances in Research on COVID-19 Vaccination for People Living with HIV. <i>Infectious Diseases & Immunity</i> , 2022, 2, 213-218.	0.2	5
1796	The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
1797	Analyzing the diffusion and duration of antibodies to SARS-CoV-2 during the natural infection and comparison with vaccination. <i>European Physical Journal Plus</i> , 2023, 138, .	1.2	0
1798	Towards Quantum-Chemical Level Calculations of SARS-CoV-2 Spike Protein Variants of Concern by First Principles Density Functional Theory. <i>Biomedicines</i> , 2023, 11, 517.	1.4	4
1799	Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 59, 152177.	1.6	3

#	ARTICLE	IF	CITATIONS
1800	Antibody responses to BNT162b2 SARS-CoV-2 mRNA vaccine among healthcare workers and residents of long-term care facilities: A cohort study in Northern Italy. <i>Health Science Reports</i> , 2023, 6, .	0.6	0
1801	Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines. <i>Vaccines</i> , 2023, 11, 417.	2.1	5
1802	Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	3
1803	Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
1804	Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age. <i>New England Journal of Medicine</i> , 2023, 388, 621-634.	13.9	33
1805	IL-10 modified mRNA monotherapy prolongs survival after composite facial allografting through the induction of mixed chimerism. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 610-627.	2.3	0
1806	Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 11, .	2.0	9
1807	Biodegradable Polyester Nanoparticle Vaccines Deliver Self-Amplifying mRNA in Mice at Low Doses. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	1
1808	Humoral immune response to SARS-CoV-2 mRNA vaccines is associated with choice of vaccine and systemic adverse reactions DMD TNR. <i>Clinical and Experimental Vaccine Research</i> , 2023, 12, 60.	1.1	0
1809	Impact of BNT162b2 Booster Dose on SARS-CoV-2 Anti-Trimeric Spike Antibody Dynamics in a Large Cohort of Italian Health Care Workers. <i>Vaccines</i> , 2023, 11, 463.	2.1	3
1810	Review on COVID-19 Vaccines. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 5868-5874.	0.2	0
1811	SARS-CoV-2 S Glycoprotein Stabilization Strategies. <i>Viruses</i> , 2023, 15, 558.	1.5	1
1812	Minimal Change Nephrotic Syndrome with Acute Kidney Injury after the Administration of Pfizer-BioNTech COVID-19 Vaccine. <i>Case Reports in Infectious Diseases</i> , 2023, 2023, 1-4.	0.2	0
1813	Evaluation of Neuroprotective and Adjuvant Activities of Diketopiperazine-Based Peptidomimetics. <i>ChemistrySelect</i> , 2023, 8, .	0.7	1
1816	Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice. <i>Microbial Cell Factories</i> , 2023, 22, .	1.9	2
1817	HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. <i>Vaccines</i> , 2023, 11, 548.	2.1	1
1818	The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2023, 42, 503-512.	1.3	1
1820	A mini review for lipid-based nanovaccines: from their design to their applications. <i>Journal of Liposome Research</i> , 2023, 33, 214-233.	1.5	1

#	ARTICLE	IF	CITATIONS
1821	Diabetes mellitus is associated with 90-day mortality in old critically ill COVID-19 patients: a multicenter prospective observational cohort study. <i>Infection</i> , 0, , .	2.3	1
1822	The comparison of SARS-CoV-2 antibody levels in medical personnel induced by different types of vaccines compared to the natural infection. <i>Central-European Journal of Immunology</i> , 0, , .	0.4	1
1823	A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
1824	Nucleotides Entrapped in Liposome Nanovesicles as Tools for Therapeutic and Diagnostic Use in Biomedical Applications. <i>Pharmaceutics</i> , 2023, 15, 873.	2.0	2
1825	Self-driving laboratories: A paradigm shift in nanomedicine development. <i>Matter</i> , 2023, 6, 1071-1081.	5.0	8
1826	A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1827	Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4796.	1.2	2
1828	Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults. <i>Nature Aging</i> , 2023, 3, 418-435.	5.3	6
1829	Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019. <i>Rheumatic Disease Clinics of North America</i> , 2023, 49, 695-711.	0.8	0
1830	Advanced Therapies for Patients with COVID-19. , 2023, , 77-92.		0
1831	Tannic Acid Lipid Nanoparticles can Deliver Messenger RNA Payloads and Improve their Endosomal Escape. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	5
1832	Exposure of low-temperature plasma after vaccination in tongue promotes systemic IgM induction against spike protein of SARS-CoV-2. <i>Free Radical Research</i> , 2023, 57, 30-37.	1.5	0
1833	Effect of a Fourth Dose of mRNA Vaccine and of Immunosuppression in Preventing SARS-CoV-2 Breakthrough Infections in Heart Transplant Patients. <i>Microorganisms</i> , 2023, 11, 755.	1.6	0
1834	Rate of COVID-19 vaccination among patients with cancer who tested positive for severe acute respiratory syndrome coronavirus 2: Analysis of the American Society of Clinical Oncology Registry. <i>Cancer</i> , 2023, 129, 1752-1762.	2.0	3
1835	mRNA therapeutics: New vaccination and beyond. <i>Fundamental Research</i> , 2023, 3, 749-759.	1.6	6
1836	Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2023, 12, 234-238.	0.6	2
1838	Short-term Side Effects of COVID-19 Vaccines (Astrazeneca, Sputnik-V, and Sinopharm) in Health Care Workers: A Cross-Sectional Study in Iran. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	0
1839	Heterologous Vector mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines. <i>Vaccines</i> , 2023, 11, 701.	2.1	3

#	ARTICLE	IF	CITATIONS
1840	COVID-19 Prevention in Solid Organ Transplant Recipients: Current State of the Evidence. <i>Infectious Disease Clinics of North America</i> , 2023, , .	1.9	1
1841	SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison. <i>Diagnostics</i> , 2023, 13, 1194.	1.3	2
1842	mRNA Vaccines against SARS-CoV-2: Advantages and Caveats. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5944.	1.8	12
1843	Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia. <i>Blood Advances</i> , 0, , .	2.5	1
1844	Third SARS-CoV-2 vaccination and breakthrough infections enhance humoral and cellular immunity against variants of concern. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1845	Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea. <i>Infection and Chemotherapy</i> , 2023, 55, 99.	1.0	0
1846	Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1847	Cytotoxic T Cells Targeting Spike Glycoprotein Are Associated with Hybrid Immunity to SARS-CoV-2. <i>Journal of Immunology</i> , 2023, 210, 1236-1246.	0.4	4
1848	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. <i>Nature Communications</i> , 2023, 14, .	5.8	31
1849	COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series. <i>IScience</i> , 2023, 26, 106506.	1.9	4
1850	Anti-S1/RBD-Specific Antibody Formation After SARS-CoV-2 Vaccination in Elderly Rheumatoid Arthritis Patients: Single-Center Prospective Observational Study. <i>Journal of Korean Medical Science</i> , 2023, 38, .	1.1	0
1852	Pre-clinical models to define correlates of protection for SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1853	Intraocular inflammation following COVID-19 vaccination: the clinical presentations. <i>International Ophthalmology</i> , 2023, 43, 2971-2981.	0.6	4
1854	Unusual delay in Kidney Transplant due to COVID-19 Pandemic Just Before Transplant Surgery. <i>Indian Journal of Transplantation</i> , 2023, 17, 127.	0.0	0
1855	Patients under medical conditions, immunogenicity and safety of covid-19 vaccines: a systematic review and meta-analysis. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2023, 10, 18-21.	0.3	0
1856	Both Feline Coronavirus Serotypes 1 and 2 Infected Domestic Cats Develop Cross-Reactive Antibodies to SARS-CoV-2 Receptor Binding Domain: Its Implication to Pan-CoV Vaccine Development. <i>Viruses</i> , 2023, 15, 914.	1.5	5
1857	Biomolecular Liquidâ€“Liquid Phase Separation for Biotechnology. <i>BioTech</i> , 2023, 12, 26.	1.3	2
1858	SARS-CoV-2 Omicron boosting induces de novo B cell response in humans. <i>Nature</i> , 2023, 617, 592-598.	13.7	49

#	ARTICLE	IF	CITATIONS
1859	Unilateral Axillary Lymphadenopathy in Cancer Patients Post-COVID-19 Vaccination: Review and Case Series. <i>Case Reports in Oncology</i> , 0, , 194-209.	0.3	0
1860	Immunology of COVID-19. , 2024, , 52-71.		0
1861	Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines. <i>Virology Journal</i> , 2023, 20, .	1.4	1
1862	Nonreplicating synthetic mRNA vaccines: A journey through the European (Journal of Immunology) history. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	2
1863	Does US full vaccination against COVID-19 immunize correspondingly S&P500 index: Evidence from the NARDL approach. <i>Heliyon</i> , 2023, 9, e15332.	1.4	0
1864	A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response. <i>Vaccines</i> , 2023, 11, 832.	2.1	1
1865	Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. <i>Lancet Regional Health - Europe</i> , The, 2023, 28, 100613.	3.0	6
1866	The Safety of COVID-19 Vaccine Accepted in Patients with Rheumatic Immune Diseases. <i>Advances in Clinical Medicine</i> , 2023, 13, 5387-5395.	0.0	0
1867	Primary Prophylaxis of COVID-19: A Comprehensive Review of approved vaccines. <i>Research Journal of Pharmacy and Technology</i> , 2023, , 917-923.	0.2	0
1868	A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. <i>Nature Communications</i> , 2023, 14, .	5.8	21
1870	Serologic response to COVID-19 infection or vaccination in pediatric kidney transplant recipients compared to healthy children. <i>Transplant Immunology</i> , 2023, 78, 101839.	0.6	2
1871	Development of SARS-CoV-2 Vaccine: Challenges and Prospects. <i>Diseases (Basel, Switzerland)</i> , 2023, 11, 64.	1.0	1
1872	Immunogenicity and protective efficacy of SARS-CoV-2 mRNA vaccine encoding secreted non-stabilized spike in female mice. <i>Nature Communications</i> , 2023, 14, .	5.8	7
1885	A profound perception into manifestation of lifesaver. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
1898	A personalized mRNA vaccine has exhibited potential in the treatment of pancreatic cancer. , 2023, 2, .		1
1916	RNA Vaccines: The Evolution, Applications, and the Challenges Ahead. , 2023, , 349-364.		1
1918	Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2023, 68, 2824-2842.	1.1	4
1926	Multiplex Immunoassay Approaches Using Luminex® xMAP® Technology for the Study of COVID-19 Disease. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 479-489.	0.8	0

#	ARTICLE	IF	CITATIONS
1931	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	2.8	13
1937	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
1939	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
1959	mRNA vaccines in disease prevention and treatment. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	9
1991	The Impact of the COVID-19 Pandemic on Pancreas Transplantation. , 2023, , 1267-1273.		0
1992	Hydrogels as biologics/gene delivery systems. , 2024, , 669-689.		0
2009	New-Onset Acute Interstitial Nephritis Post-SARS-CoV-2 Infection and COVID-19 Vaccination: A Panoramic Review. <i>Journal of Epidemiology and Global Health</i> , 0, , .	1.1	0
2015	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
2036	Detection of Covid-19 Vaccination Effect Through Proteomic Approaches in Cancer Patients. , 2023, , .		0
2054	Nichtvirale Vektoren. , 2023, , 87-102.		0
2057	Breaking the mold with RNAâ€™a â€™œRNAissanceâ€™ of life science. <i>Npj Genomic Medicine</i> , 2024, 9, .	1.7	0
2060	mRNA vaccines: a promising solution for incurable diseases. , 2024, , .		0
2070	An introduction to RNA therapeutics and their potentials. <i>Progress in Molecular Biology and Translational Science</i> , 2024, , 1-12.	0.9	0